



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/574, 33/53, C12Q 1/68		A1	(11) International Publication Number: WO 97/42506 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/US97/07467 (22) International Filing Date: 2 May 1997 (02.05.97)		(81) Designated States: CA, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/016,564 3 May 1996 (03.05.96) US		Published <i>With international search report.</i>	
(71) Applicant (<i>for all designated States except US</i>): THOMAS JEFFERSON UNIVERSITY [US/US]; 11th and Walnut Streets, Philadelphia, PA 19107 (US).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): WALDMAN, Scott, A. [US/US]; 119 Bleddyn Road, Ardmore, PA 19003 (US). CARRITHERS, Stephen, L. [US/US]; University of Kentucky at Louisville, Louisville, KY 40292 (US).			
(74) Agents: JOHNSON, Philip, S. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).			
(54) Title: METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS AND METASTASIS THEREOF			
(57) Abstract			
<p><i>In vitro</i> methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. <i>In vitro</i> methods of determining whether or not tumor cells are colorectal in origin are disclosed. <i>In vitro</i> kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such <i>in vitro</i> kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.</p>			
BEST AVAILABLE COPY			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING
COLORECTAL TUMORS AND METASTASIS THEREOF**

FIELD OF THE INVENTION

The present invention relates to compositions and kits for and methods of detecting metastasized colorectal tumor cells in samples. The present invention also relates to compositions and kits for and methods of evaluating the extent of invasive activity of colorectal tumor cells in samples from the colon.

10 BACKGROUND OF THE INVENTION

Colorectal cancer is the third most common neoplasm worldwide and the second most common in the United States, representing about 15% of the newly diagnosed cases of cancer in the United States. The large intestine or large bowel is the third leading site for the development of new cancer and is diagnosed in about 150,000 patients each year. Colorectal cancer is the second leading cause of cancer-related deaths and is responsible for about 12% of cancer deaths in the United States. The mortality rate of newly diagnosed large bowel cancer approaches 50% and there has been little improvement over the past 40 years. Most of this mortality reflects local, regional and distant metastases. About thirty percent of patients with colorectal cancer have unresectable disease at presentation and about 40% develop metastases during the course of their disease. Distant metastatic disease is seen in liver (about 12%), lung (about 3%), bone (about 0.9%), brain (about

0.7%), nodes (about 4%), and peritoneum (about 2%) at the time of initial diagnosis. In 1987, the large bowel cancers found regionally or at distant sites at the time of diagnosis were about 26% and about 18%, respectively.

5 Surgery is the mainstay of treatment for colorectal cancer but recurrence is frequent. Colorectal cancer has proven resistant to chemotherapy, although limited success has been achieved using a combination of 5-fluorouracil and levamisole. Surgery has had the largest impact on survival
10 and, in some patients with limited disease, achieves a cure. However, surgery removes bulk tumor, leaving behind microscopic residual disease which ultimately results in recrudescence. Overall recurrence rates for colonic tumors are about 33% and for rectal cancer about 42%. Of these recurrences, about 9%
15 are local, about 13% are systemic metastatic disease, and the remaining 88% are a combination of local and systemic disease. Fifty percent of patients with recurrent colorectal cancer have hepatic metastases.

Early detection of primary, metastatic, and recurrent
20 disease can significantly impact the prognosis of individuals suffering from colorectal cancer. Large bowel cancer diagnosed at an early stage has a significantly better outcome than that diagnosed at more advanced stages. The 5 year relative survival rates for patients with regional or distant metastases
25 are 48% and 5%, compared with 90% and 77% for disease which is *in situ* or local, respectively, at the time of diagnosis. Similarly, diagnosis of metastatic or recurrent disease earlier potentially carries with it a better prognosis.

Immunoscintigraphy using monoclonal antibodies
30 directed at tumor-specific markers has been employed to diagnose colorectal cancer. Monoclonal antibodies against carcinoembryonic antigen (CEA) labeled with ⁹⁹Technetium identified 94% of patients with recurrent tumors. Similarly,
35 ¹¹¹Indium-labeled anti-CEA monoclonal antibodies successfully diagnosed 85% of patients with recurrent colorectal carcinoma who were not diagnosed by conventional techniques. ¹²⁵Iodine-labeled antibodies have been effective in localizing more than

80% of the pathologically-confirmed recurrences by intraoperative gamma probe scanning.

There remains a need for compositions and kits which can specifically detect metastasized colorectal cancer cells 5 using samples removed from or discharged by an individual being screened for, suspected of suffering from or suspected of being susceptible to metastasized colorectal tumors. There remains a need for methods of identifying individuals suffering from metastasized colorectal tumors using samples removed from or 10 discharged by an individual being screened for, suspected of suffering from or suspected of being susceptible to metastasized colorectal tumors.

SUMMARY OF THE INVENTION

The present invention relates to *in vitro* methods of 15 determining whether or not an individual has metastasized colorectal cancer cells. The present invention relates to *in vitro* methods of examining samples of extraintestinal tissue and body fluids from an individual to determine whether or not ST receptor protein, which is a protein that is specific to 20 colorectal cells including colorectal tumor cells, is being expressed extraintestinally. The presence of specific sequences of the ST receptor protein or of nucleic acid molecules that encode specific sequences of ST receptor protein and that are indicative of expression of the ST receptor 25 protein is evidence that the individual is suffering from metastasized colorectal cancer. According to the present invention, methods and compositions are provided for detecting either 1) the extracellular portion of the ST receptor protein (amino acids 24-430 of SEQ ID NO:2), 2) the 63 carboxy terminal 30 amino acid sequence of the ST receptor protein (amino acids 1031-1093 of SEQ ID NO:2), 3) the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 which are encoded by nucleotides 72-1290 of SEQ ID NO:1), or 4) the mRNA sequence that the 63 carboxy terminal 35 amino acid sequence of the ST receptor protein (amino acids

1031-1093 which are encoded by nucleotides 3091-3274 of SEQ ID NO:1).

The present invention relates to *in vitro* methods of determining whether or not tumor cells are colorectal in origin. The present invention relates to *in vitro* methods of diagnosing whether or not an individual suffering from cancer is suffering from colorectal cancer. The present invention relates to *in vitro* methods of examining samples of tumors from an individual to determine whether or not ST receptor protein, which is a protein that is specific to colorectal cells including colorectal tumor cells, is being expressed by the tumor cells. The presence of the ST receptor protein or of nucleic acid molecules that are indicative of expression of the ST receptor protein is evidence that the individual is suffering from colorectal cancer. The presence of the ST receptor protein or mRNA encoding the ST receptor is determined by identifying the presence of either 1) the extracellular portion of the ST receptor protein (amino acids 24-430), 2) the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093), 3) the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 encoded by nucleotides 72-1290), or 4) the mRNA sequence that the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093 encoded by nucleotides 3091-3274).

The present invention relates to *in vitro* kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such *in vitro* kits of the invention. According to the present invention, *in vitro* kits and reagents are provided for practicing methods detecting, in a sample, the presence of either 1) the extracellular portion of the ST receptor protein (amino acids 24-430), 2) the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093), 3) the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 encoded by nucleotides 72-1290), or 4) the mRNA sequence

that the 63 carboxy terminal amino acid sequence (amino acids 1031-1093 encoded by nucleotides 3091-3274) of the ST receptor protein.

In some embodiments of the invention, extraintestinal tissue and fluid samples, i.e. non-colorectal tissue and fluid samples, may be screened to identify the presence or absence of the ST receptor protein. Techniques such as an ST receptor/ligand binding assays, ELISA assays and Western blots may be performed to determine whether the ST receptor is present in a sample. According to the present invention, the presence or absence of either the extracellular portion of the ST receptor protein (amino acids 24-430), or the 63 carboxy terminal amino acid sequence of the ST receptor protein may be detected (amino acids 1031-1093).

In some embodiments of the invention, extraintestinal tissue and fluid samples, i.e. non-colorectal tissue and fluid samples, may be screened to identify whether ST receptor protein is being expressed in extraintestinal cells by detecting the presence or absence of mRNA that encodes the ST receptor protein. The presence of mRNA that encodes the ST receptor protein or cDNA generated therefrom can be determined using techniques such as PCR amplification including RT-PCR amplification, Northern Blots (mRNA), Southern Blots (cDNA), oligonucleotide hybridization ribonuclease protection assay (RPA), *in situ* PCR or hybridization, S1-nuclease protection assay, immune-capture RT-PCR, nucleic acid sequence-based amplification (NASBA), branched DNA (bDNA) technology, and strand-displacement amplification (SDA). According to the present invention, the presence or absence of either the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 encoded by nucleotides 72-1290), or the mRNA sequence that the 63 carboxy terminal amino acid sequence of the ST receptor protein may be detected (amino acids 1031-1093 encoded by nucleotides 3091-3274).

In some embodiments of the invention, cells of extraintestinal tissue samples, i.e. non-colorectal tissue samples, may be examined to identify the presence or absence of

the ST receptor protein. Techniques such as an ST receptor/ligand binding or immunohistochemistry blots may be performed on tissue sections to determine whether the ST receptor is present in a sample. According to the present invention, the presence or absence of either the extracellular portion of the ST receptor protein (amino acids 24-430), or the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093) may be detected.

In some embodiments of the invention, cells of extraintestinal tissue samples, i.e. non-colorectal tissue samples, may be examined to determine whether ST receptor protein is being expressed in extraintestinal cells by detecting the presence or absence of mRNA that encodes the ST receptor protein. The presence of mRNA that encodes the ST receptor protein or cDNA generated therefrom in cells from tissue sections can be determined using techniques such as *in situ* hybridization. According to the present invention, the presence or absence of either the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 encoded by nucleotides 72-1290), or the mRNA sequence that the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093 encoded by nucleotides 3091-3274) may be detected.

Another aspect of the invention relates to methods of analyzing tissue samples from the colon tissue to evaluate the extent of metastasis or invasion of colorectal tumor cells into the lamina propria. The lamina propria represents the barrier between the colorectal tract and the rest of the body; see *Bailey's Textbook of Histology*, 16th edition, Coperhaven et al. 1975 Williams and Wilkins, Baltimore MD at page 404 which is incorporated herein by reference. By identifying the presence of ST receptor or mRNA that encodes ST receptor protein in cells of the lamina propria, the extent of invasion/infiltration of colorectal tumor cells into extraintestinal tissue can be evaluated and confirmed. According to the present invention, the presence or absence of either 1) the extracellular portion of the ST receptor protein (amino acids 24-430), 2) the 63

carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093), 3) the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 24-430 encoded by nucleotides 72-1290), or 4) the mRNA sequence 5 that the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093 encoded by nucleotides 3091-3274) may be detected in cells of the laminapropria.

The present invention relates to *in vitro* kits for evaluating tissues samples to determine the level of metastasis 10 and to reagents and compositions useful to practice the same.

In some embodiments of the invention, tissue samples which include sections of the laminapropria may be isolated from individuals undergoing or recovering from surgery to remove colorectal tumors. The tissue is analyzed to determine the 15 extent of invasion into the basement membrane of the laminapropria by neoplastic colorectal cells. Identification of the presence or absence of the ST receptor protein confirms evaluation of the migration of tumor cells into the basement membrane indicating metastasis. Techniques such as an ST 20 receptor/ligand binding and immunohistochemistry assays may be performed to determine whether the ST receptor is present in cells in the tissue sample which are indicative of metastatic migration. Alternatively, in some embodiments of the invention, tissue samples that include the laminapropria are 25 analyzed to identify whether ST receptor protein is being expressed in cells in the tissue sample which indicates metastatic migration by detecting the presence or absence of mRNA that encodes the ST receptor protein. The presence of mRNA that encodes the ST receptor protein or cDNA generated 30 therefrom can be determined using techniques such as *in situ* hybridization. According to the present invention, the presence or absence of either 1) the extracellular portion of the ST receptor protein (amino acids 24-430), 2) the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093), 3) the mRNA sequence that encodes the extracellular portion of the ST receptor protein (amino acids 35 24-430 encoded by nucleotides 72-1290), or 4) the mRNA sequence

that the 63 carboxy terminal amino acid sequence of the ST receptor protein (amino acids 1031-1093 encoded by nucleotides 3091-3274), may be detected in cells of tissue to determine the extent of invasion into the basement membrane of the 5 laminapropria by neoplastic colorectal cells.

DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

As used herein, the terms "ST" and "native ST" are used interchangeably and are meant to refer to heat-stable toxin (ST) which is a peptide produced by *E. coli*, as well as 10 other organisms. STs are naturally occurring peptides which 1) are naturally produced by organisms, 2) which bind to the ST receptor and 3) which activate the signal cascade that mediates ST-induced diarrhea.

As used herein, the term "ST receptor" is meant to 15 refer to the receptors found on colorectal cells, including local and metastasized colorectal cancer cells, which bind to ST. In normal individuals, ST receptors are found exclusively in cells of intestine, in particular in cells in the duodenum, small intestine (jejunum and ileum), the large intestine, colon 20 (cecum, ascending colon, transverse colon, descending colon and sigmoid colon) and rectum. The nucleotide sequence that encodes human ST receptor protein has been cloned and the amino acid and nucleotide sequences are described in F.J. Sauvage et al. 1991 *J. Biol. Chem.* 266:17912-17918, each of which is 25 incorporated herein by reference.

As used herein, the term "extracellular portion of the ST receptor" is meant to refer to, from N terminal to C terminal, amino acids 24-430 of the ST receptor protein.

As used herein, amino acids 24-430 is meant to refer 30 to amino acids 24-430 of SEQ ID NO:2 or the corresponding sequences from an allelic variant of ST receptor protein.

As used herein, nucleotides 72-1290 is meant to refer to nucleotides 72-1290 of SEQ ID NO:1 or the corresponding sequences from an allelic variant of ST receptor protein.

35 As used herein, the term "carboxy tail of the ST receptor" is meant to refer to, from N terminal to C terminal,

the 63 most C terminal amino acids of the ST receptor protein, i.e. amino acids 1031-1093 of the ST receptor protein.

As used herein, amino acids 1031-1093 is meant to refer to amino acids 1031-1093 of SEQ ID NO:2 or the 5 corresponding sequences from an allelic variant of ST receptor protein.

As used herein, nucleotides 3091-3274 is meant to refer to nucleotides 3091-3274 of SEQ ID NO:1 or the corresponding sequences from an allelic variant of ST receptor 10 protein.

As used herein, the term "ST receptor ligand" is meant to refer to compounds which specifically bind to the ST receptor. ST is an ST receptor ligand. An ST receptor ligand may be a peptide or a non-peptide. ST receptor ligands are 15 described in U.S. Patent Application Serial Number 08/141,892, filed October 26, 1993, which is incorporated herein by reference.

As used herein, the term "ST receptor binding peptide" is meant to refer to ST receptor ligands that are peptides.

As used herein, the term "ST peptides" is meant to refer to ST receptor binding peptides described in U.S. Patent Application Serial Number 08/141,892, filed October 26, 1993 which is incorporated herein by reference, U.S. Patent Application Serial Number 08/305,056 filed September 13, 1994 25 which is incorporated herein by reference, and PCT Application Serial Number PCT/US94/12232 filed October 26, 1994 and published as International Publication Serial Number WO 95/11694 with International Publication Date May 4, 1996, which is incorporated herein by reference.

As used herein, the term "fragment" is meant to refer 30 to peptide a) which has an amino acid sequence identical to a portion of an ST receptor binding peptide and b) which is capable of binding to the ST receptor.

As used herein, the term "derivative" is meant to 35 refer to a peptide a) which has an amino acid sequence substantially identical to at least a portion of an ST receptor

binding peptide and b) which is capable of binding to the ST receptor.

As used herein, the term "substantially identical" is meant to refer to an amino acid sequence that is the same as 5 the amino acid sequence of an ST peptide except some of the residues are deleted or substituted with conservative amino acids or additional amino acids are inserted.

As used herein, the term "colorectal cancer" is meant to include the well-accepted medical definition that defines 10 colorectal cancer as a medical condition characterized by cancer of cells of the intestinal tract below the small intestine (i.e. the large intestine (colon), including the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon, and rectum). Additionally, as used herein, the 15 term "colorectal cancer" is meant to further include medical conditions which are characterized by cancer of cells of the duodenum and small intestine (jejunum and ileum). The definition of colorectal cancer used herein is more expansive than the common medical definition but is provided as such 20 since the cells of the duodenum and small intestine also contain ST receptors and are therefore amenable to the methods of the present invention using the compounds of the present invention.

As used herein, the term "metastasis" is meant to 25 refer to the process in which cancer cells originating in one organ or part of the body relocate to another part of the body and continue to replicate. Metastasized cells subsequently form tumors which may further metastasize. Metastasis thus refers to the spread of cancer from the part of the body where 30 it originally occurs to other parts of the body. The present invention relates to methods of delivering active agents to metastasized colorectal cancer cells.

As used herein, the term "metastasized colorectal cancer cells" is meant to refer to colorectal cancer cells 35 which have metastasized; colorectal cancer cells localized in a part of the body other than the duodenum, small intestine (jejunum and ileum), large intestine (colon), including the

cecum, ascending colon, transverse colon, descending colon, and sigmoid colon, and rectum.

As used herein, the term "non-colorectal sample" and "extra-intestinal sample" are used interchangeably and meant to refer to a sample of tissue or body fluid from a source other than colorectal tissue. In some preferred embodiments, the extra-intestinal sample is a sample of tissue such as lymph nodes. In some preferred embodiments, the non-colorectal sample is a sample of extra-intestinal tissue which is an adenocarcinoma of unconfirmed origin. In some preferred embodiments, the extra-intestinal sample is a blood sample.

As used herein, "an individual suffering from an adenocarcinoma of unconfirmed origin" is meant to refer to an individual who has a tumor in which the origin has not been definitively identified.

As used herein, "an individual is suspected of being susceptible to metastasized colorectal cancer" is meant to refer to an individual who is at a particular risk of developing metastasized colorectal cancer. Examples of individuals at a particular risk of developing metastasized colorectal cancer are those whose family medical history indicates above average incidence of colorectal cancer among family members and/or those who have already developed colorectal cancer and have been effectively treated who therefore face a risk of relapse and recurrence.

Advancements in the understanding of genetics and developments in technology as well as epidemiology allow for the determination of probability and risk assessment an individual has for developing colorectal cancer. Using family health histories and/or genetic screening, it is possible to estimate the probability that a particular individual has for developing certain types of cancer including colorectal cancer. Those individuals that have been identified as being predisposed to developing a particular form of cancer can be monitored or screened to detect evidence of metastasized colorectal cancer. Upon discovery of such evidence, early treatment can be undertaken to combat the disease.

Similarly, those individuals who have already developed colorectal cancer and who have been treated to remove the cancer or are otherwise in remission are particularly susceptible to relapse and reoccurrence including the 5 metastasis of tumors. Such individuals can be monitored and screened to detect evidence of metastasis and upon discovery of such evidence, early treatment can be undertaken to combat the disease.

ST, which is produced by *E. coli*, as well as other 10 organisms, is responsible for endemic diarrhea in developing countries and travelers diarrhea. ST induces intestinal secretion by binding to specific receptors, ST receptors, in the apical brush border membranes of the mucosal cells lining the intestinal tract. Binding of ST to ST receptors is non-15 covalent and occurs in a concentration-dependent and saturable fashion. Once bound, ST-ST receptor complexes appear to be internalized by intestinal cells, i.e. transported from the surface into the interior of the cell. Binding of ST to ST receptors triggers a cascade of biochemical reactions in the 20 apical membrane of these cells resulting in the production of a signal which induces intestinal cells to secrete fluids and electrolytes, resulting in diarrhea.

ST receptors are unique in that they are only localized in the apical brush border membranes of the cells 25 lining the intestinal tract. Indeed, they are not found in any other cell type in placental mammals. In addition, ST receptors are almost exclusively localized to the apical membranes, with little being found in the basolateral membranes on the sides of intestinal cells.

30 Mucosal cells lining the intestine are joined together by tight junctions which form a barrier against the passage of intestinal contents into the blood stream and components of the blood stream into the intestinal lumen.

In individuals suffering from colorectal cancer, the 35 cancer cells are often derived from cells that produce and display the ST receptor and these cancer cells continue to produce and display the ST receptor on their cell surfaces.

Indeed, T84 cells, which are human colonic adenocarcinoma cells isolated from lung metastases, express ST receptors on their cell surface. Similarly, HT29glu-cells, which are human colonic adenocarcinoma cells, express receptors for ST. Thus, 5 in individuals suffering from colorectal cancer, some metastasized intestinal cancer cells express ST receptors.

An effort was undertaken to determine the proportion of colorectal tumors which have the ST receptor. Each of the tumors tested were independently confirmed to be colorectal 10 cancer by standard techniques of surgical pathology. Every one of the colorectal cancer tumors tested, including local colorectal tumors and metastasized tumors (liver, lung, lymph node, peritoneum, gall bladder), possessed ST receptors. In each case, the affinity and density of receptors was amenable 15 for targeting. That is, the cells possessed at least 10^4 - 10^6 receptors per cell and demonstrated an affinity of 10^{-7} or better (that is preferably between 10^{-8} to 10^{-9} or less; the lower number indicating a tighter bond, thus a higher affinity). Normal liver, lymph node, peritoneum and lung cells 20 were found not to possess ST receptors.

When such cancer cells metastasize, the metastasized cancer cells continue to produce and display the ST receptor. The expression of ST receptors on the surfaces of metastatic tumors provides a target for selective binding of conjugated 25 compositions. ST receptors permit the absolutely specific targeting of diagnostic agents to metastatic colorectal cancer cells.

ST receptor protein and mRNA encoding ST receptor protein permit the absolutely specific targeting of diagnostic 30 agents to metastatic colorectal cancer cells.

According to the present invention, specific portions of ST receptor protein and specific mRNA sequences that encode specific portions of the ST receptor protein provide the means to more specifically and accurately target metastatic 35 colorectal cancer cells using diagnostic tools. These portions refer specifically to the extracellular membrane portion of the ST receptor protein and the tail of the ST receptor protein.

In some embodiments, diagnostic methods and kits of the present invention are specifically targeted to detecting metastatic disease. In other embodiments, methods and kits are provided for evaluating whether or not a tumor is colorectal in 5 origin. In other embodiments, methods and kits are provided for evaluating the metastatic migration of tumor cells in the laminapropria, indicating the level of invasion of colorectal tumor cells into the basement membrane.

According to the invention, compounds are provided 10 which bind to ST receptor protein or mRNA encoding the receptor. Normal tissue in the body does not have ST receptors or mRNA encoding ST receptors except cells of the intestinal tract. Thus, if extraintestinal samples possess ST receptors metastasis of colorectal tumor cells is indicated. Thus, 15 metastasized colorectal cells may be identified by detecting in extraintestinal samples ST receptors or mRNA encoding ST receptors. The expression of ST receptor is a marker for cell type and allows for the identification of colorectal metastasis in extra-intestinal samples. Moreover, expression of ST 20 receptor is a marker for cell type and allows for the identification of the origin of adenocarcinoma of unconfirmed origin as colorectal tumors. Additionally, expression of ST receptor is useful to visualize and confirm the invasion of colorectal neoplasms into the basement membrane of the 25 laminapropria.

Patients

Patients with adenocarcinomas:

The invention can be used to identify colorectal tumors in samples of tumors removed from individuals suffering 30 from adenocarcinomas of unconfirmed origin.

Screening/monitoring Patients:

Individuals who are at risk for developing metastasized colorectal cancer may be screened using the in vitro diagnostic methods of the present invention. The 35 invention is particularly useful for monitoring individuals whose family medical history includes relatives who have suffered from colorectal cancer. Likewise, the invention is

useful to monitor individuals who have been diagnosed as having colorectal cancer and, particularly those who have been treated and had tumors removed and/or are otherwise experiencing remission.

5 Surgical patients to be evaluated:

For aspects of the invention related to analysis of lumen tissue, the invention is useful to evaluate the level of metastatic migration of colorectal tumor cells using lumen samples taken from surgery patients at and near the site of the
10 tumor.

Samples

Tissue Samples:

Non-colorectal tissue samples may be obtained from any extraintestinal tissue, i.e. tissue from sites other than those
15 in the intestinal tract below the small intestine (i.e. the large intestine (colon), including the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon, and rectum) and additionally the duodenum and small intestine (jejunum and ileum). The cells of all tissues except those of
20 that are intestinal do not express the ST receptor. Thus if the ST receptor protein or mRNA encoding the ST receptor protein are detected in extraintestinal samples, the presence of metastatic colorectal cancer cells is indicated. In some preferred embodiments, the tissue samples are lymph nodes.

25 Tissue samples may be obtained by standard surgical techniques including use of biopsy needles. One skilled in the art would readily appreciate the variety of test samples that may be examined for ST receptor protein and recognize methods of obtaining tissue samples.

30 Tissue samples may be homogenized or otherwise prepared for screening for the presence of ST receptor protein by well known techniques such as sonication, mechanical disruption, chemical lysis such as detergent lysis or combinations thereof.

35 Tumor samples:

Samples from tumors may be identified as colorectal in origin by identification of expression of ST receptors using

the methods of the invention. Samples of tumors removed from individuals suffering from adenocarcinomas of unconfirmed origin can be tested to determine whether or not they possess ST receptor protein or mRNA encoding ST receptor protein. If 5 the sample is removed from the intestinal track, a section of frozen cells can be examined to determine if the tumor cells express ST receptor protein. If the sample is removed from the extra-intestinal tissue, a section of frozen cells can be examined to determine if the tumor cells express ST receptor 10 protein or the sample can be homogenized and tested since the non-cancer cells will not possess ST receptors and therefore not present background.

Samples may be obtained from resected tissue or biopsy material including needle biopsy. Tissue section preparation 15 for surgical pathology may be frozen and prepared using standard techniques. In ST binding assays on tissue sections, ST is added before fixing cells. Immunohistochemistry and *in situ* hybridization binding assays on tissue sections are performed in fixed cells. Extra-intestinal samples may be 20 homogenized by standard techniques such as sonication, mechanical disruption or chemical lysis such as detergent lysis. It is also contemplated that tumor samples in body fluids, excretions and/or secretion such as blood, urine, lymph fluid, cerebral spinal fluid, amniotic fluid, vaginal fluid, 25 semen and stool samples may also be screened to determine if such tumors are colorectal in origin.

Body fluid samples:

Examples of body fluid samples include blood, urine, lymph fluid, cerebral spinal fluid, amniotic fluid, vaginal 30 fluid and semen. In some preferred embodiments, blood is used as a sample of body fluid. Cells may be isolated from fluid sample such as centrifugation. One skilled in the art would readily appreciate the variety of test samples that may be examined for ST receptor protein. Test samples may be obtained 35 by such methods as withdrawing fluid with a syringe or by a swab. One skilled in the art would readily recognize other methods of obtaining test samples.

In an assay using a blood sample, the blood plasma may be separated from the blood cells. The blood plasma may be screened for ST receptor protein including truncated protein which is released into the blood when the ST receptor protein 5 is cleaved from or sloughed off from metastasized colorectal tumor cells. In some embodiments, blood cell fractions are screened for the presence of metastasized colorectal tumor cells. In some embodiments, lymphocytes present in the blood cell fraction are screened by lysing the cells and detecting 10 the presence of ST receptor protein or mRNA encoding ST receptor protein which may be present as a result of the presence of any metastasized colorectal tumor cells that may have been engulfed by the blood cell.

Laminapropria tissue samples:

15 Samples of the laminapropria are removed during colorectal tumor removal surgery such as by resection or colonoscopy. The sample including basement membrane cells is frozen. If an ST binding assay is to be performed, the labelled ST is contacted to the frozen section and the cells 20 are then fixed and stained. If immunohistochemistry or *in situ* hybridization is to be performed, the frozen section is stained and then the assay is run. Those having ordinary skill in the art can readily isolate samples which include portions of the laminapropria and fix and stain them using standard techniques.

25 By adding the visualization provided with an ST receptor detection technique, the section can be more comprehensively analyzed and the level of invasion of neoplastic colorectal cells into the laminapropria can be determined. The present invention may be used to analyze and evaluate the extent of 30 progression of localized colorectal tumors, that is primary or non-metastatic colorectal tumors, if these have penetrated the basement membrane underlying the mucosa into the submucosa.

Assays

Immunoassay:

35 The present invention relates to immunoassay methods of identifying individuals suffering from colorectal cancer metastasis by detecting presence of ST receptor protein in

samples of extraintestinal tissue or body fluids using antibodies which were produced in response to exposure to ST receptor protein.

The present invention also relates to immunoassay methods of identifying individuals suffering from colorectal cancer by detecting the presence of ST receptor protein in samples of tumor using antibodies which were produced in response to exposure to ST receptor protein.

The antibodies are preferably monoclonal antibodies. The antibodies are preferably raised against ST receptor protein made in human cells. Immunoassays are well known and their design may be routinely undertaken by those having ordinary skill in the art. Those having ordinary skill in the art can produce monoclonal antibodies which specifically bind to ST receptor protein and are useful in methods and kits of the invention using standard techniques and readily available starting materials. The techniques for producing monoclonal antibodies are outlined in Harlow, E. and D. Lane, (1988) *ANTIBODIES: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, which is incorporated herein by reference, and which provides detailed guidance for the production of hybridomas and monoclonal antibodies which specifically bind to target proteins. It is within the scope of the present invention to include FAbs and F(AB)2s which specifically bind to ST receptor in place of antibodies.

Briefly, the ST receptor protein is injected into mice. The spleen of the mouse is removed, the spleen cells are isolated and fused with immortalized mouse cells. The hybrid cells, or hybridomas, are cultured and those cells which secrete antibodies are selected. The antibodies are analyzed and, if found to specifically bind to the ST receptor protein, the hybridoma which produces them is cultured to produce a continuous supply of anti-ST receptor protein-specific antibodies.

The present invention relates to antibodies which are produced in response to exposure to ST receptor protein. The antibodies are preferably monoclonal antibodies. The

antibodies are preferably raised against ST receptor protein made in human cells. In some embodiments, antibodies specifically bind to the extracellular domain of ST receptor protein. In some embodiments, antibodies specifically bind to 5 the transmembrane domain. In some embodiments, antibodies specifically bind to the cytoplasmic domain. The antibodies preferably bind to the extracellular domain of ST receptor protein. In particular, the antibodies preferably bind to amino acids 24-430 of ST receptor protein. In some 10 embodiments, the antibodies bind to the C-terminal tail of ST receptor protein, i.e. amino acids 1031-1093.

The means to detect the presence of a protein in a test sample are routine and one having ordinary skill in the art can detect the presence or absence of a protein or an 15 antibody using well known methods. One well known method of detecting the presence of a protein is an immunoassay. One having ordinary skill in the art can readily appreciate the multitude of ways to practice an immunoassay to detect the presence of ST receptor protein in a sample.

20 According to some embodiments, immunoassays comprise allowing proteins in the sample to bind a solid phase support such as a plastic surface. Detectable antibodies, preferably those which bind to the extracellular domain (amino acids 24-430) are then added which selectively binding to the ST 25 receptor protein. Detection of the detectable antibody indicates the presence of ST receptor protein. The detectable antibody may be a labeled or an unlabelled antibody. Unlabelled antibody may be detected using a second, labelled antibody that specifically binds to the first antibody or a 30 second, unlabelled antibody which can be detected using labelled protein A, a protein that complexes with antibodies. Various immunoassay procedures are described in *Immunoassays for the 80's*, A. Voller et al., Eds., University Park, 1981, which is incorporated herein by reference.

35 Simple immunoassays may be performed in which a solid phase support is contacted with the test sample. Any proteins present in the test sample bind the solid phase support and can

be detected by a specific, detectable antibody preparation. Such a technique is the essence of the dot blot, Western blot and other such similar assays.

Other immunoassays may be more complicated but actually provide excellent results. Typical and preferred immunometric assays include "forward" assays for the detection of a protein in which a first anti-protein antibody bound to a solid phase support is contacted with the test sample. After a suitable incubation period, the solid phase support is washed to remove unbound protein. A second, distinct anti-protein antibody is then added which is specific for a portion of the specific protein not recognized by the first antibody. The second antibody is preferably detectable. After a second incubation period to permit the detectable antibody to complex with the specific protein bound to the solid phase support through the first antibody, the solid phase support is washed a second time to remove the unbound detectable antibody. Alternatively, the second antibody may not be detectable. In this case, a third detectable antibody, which binds the second antibody is added to the system. This type of "forward sandwich" assay may be a simple yes/no assay to determine whether binding has occurred or may be made quantitative by comparing the amount of detectable antibody with that obtained in a control. Such "two-site" or "sandwich" assays are described by Wide, *Radioimmune Assay Method*, Kirkham, Ed., E. & S. Livingstone, Edinburgh, 1970, pp. 199-206, which is incorporated herein by reference.

Other types of immunometric assays are the so-called "simultaneous" and "reverse" assays. A simultaneous assay involves a single incubation step wherein the first antibody bound to the solid phase support, the second, detectable antibody and the test sample are added at the same time. After the incubation is completed, the solid phase support is washed to remove unbound proteins. The presence of detectable antibody associated with the solid support is then determined as it would be in a conventional "forward sandwich" assay. The

simultaneous assay may also be adapted in a similar manner for the detection of antibodies in a test sample.

The "reverse" assay comprises the stepwise addition of a solution of detectable antibody to the test sample 5 followed by an incubation period and the addition of antibody bound to a solid phase support after an additional incubation period. The solid phase support is washed in conventional fashion to remove unbound protein/antibody complexes and unreacted detectable antibody. The determination of detectable 10 antibody associated with the solid phase support is then determined as in the "simultaneous" and "forward" assays. The reverse assay may also be adapted in a similar manner for the detection of antibodies in a test sample.

The first component of the immunometric assay may be 15 added to nitrocellulose or other solid phase support which is capable of immobilizing proteins. The first component for determining the presence of ST receptor in a test sample is anti-ST receptor antibody. By "solid phase support" or "support" is intended any material capable of binding proteins. 20 Well-known solid phase supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the support can be either soluble to some extent or insoluble for the purposes of the present 25 invention. The support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Those skilled in the art will know many other suitable "solid phase supports" 30 for binding proteins or will be able to ascertain the same by use of routine experimentation. A preferred solid phase support is a 96-well microtiter plate.

To detect the presence of ST receptor protein, detectable anti-ST receptor antibodies are used. Several 35 methods are well known for the detection of antibodies.

One method in which the antibodies can be detectably labeled is by linking the antibodies to an enzyme and

subsequently using the antibodies in an enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA), such as a capture ELISA. The enzyme, when subsequently exposed to its substrate, reacts with the substrate and generates a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means. Enzymes which can be used to detectably label antibodies include, but are not limited to malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. One skilled in the art would readily recognize other enzymes which may also be used.

Another method in which antibodies can be detectably labeled is through radioactive isotopes and subsequent use in a radioimmunoassay (RIA) (see, for example, Work, T.S. et al., *Laboratory Techniques and Biochemistry in Molecular Biology*, North Holland Publishing Company, N.Y., 1978, which is incorporated herein by reference). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention are ^3H , ^{125}I , ^{131}I , ^{35}S , and ^{14}C . Preferably ^{125}I is the isotope. One skilled in the art would readily recognize other radioisotopes which may also be used.

It is also possible to label the antibody with a fluorescent compound. When the fluorescent-labeled antibody is exposed to light of the proper wave length, its presence can be detected due to its fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, α -phthaldehyde and fluorescamine. One skilled in the art would readily recognize other fluorescent compounds which may also be used.

Antibodies can also be detectably labeled using fluorescence-emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the protein-specific antibody using such metal chelating groups as 5 diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). One skilled in the art would readily recognize other fluorescence-emitting metals as well as other metal chelating groups which may also be used.

Antibody can also be detectably labeled by coupling 10 to a chemiluminescent compound. The presence of the chemiluminescent-labeled antibody is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, 15 theromatic acridinium ester, imidazole, acridinium salt and oxalate ester. One skilled in the art would readily recognize other chemiluminescent compounds which may also be used.

Likewise, a bioluminescent compound may be used to 20 label antibodies. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes 25 of labeling are luciferin, luciferase and aequorin. One skilled in the art would readily recognize other bioluminescent compounds which may also be used.

Detection of the protein-specific antibody, fragment or derivative may be accomplished by a scintillation counter 30 if, for example, the detectable label is a radioactive gamma emitter. Alternatively, detection may be accomplished by a fluorometer if, for example, the label is a fluorescent material. In the case of an enzyme label, the detection can be accomplished by colorometric methods which employ a substrate 35 for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards. One skilled

in the art would readily recognize other appropriate methods of detection which may also be used.

The binding activity of a given lot of antibodies may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Positive and negative controls may be performed in which known amounts of ST receptor protein and no ST receptor protein, respectively, are added to assays being performed in parallel with the test assay. One skilled in the art would have the necessary knowledge to perform the appropriate controls.

ST receptor protein may be produced as a reagent for positive controls routinely. One skilled in the art would appreciate the different manners in which the ST receptor protein may be produced and isolated.

An "antibody composition" refers to the antibody or antibodies required for the detection of the protein. For example, the antibody composition used for the detection of ST receptor in a test sample comprises a first antibody that binds ST receptor protein, preferably at the extracellular domain (amino acids 24-430) as well as a second or third detectable antibody that binds the first or second antibody, respectively.

To examine a test sample for the presence of ST receptor protein, a standard immunometric assay such as the one described below may be performed. A first anti-ST receptor protein antibody, which recognizes a specific portion of ST receptor such as the extracellular or cytoplasmic portion, is added to a 96-well microtiter plate in a volume of buffer. The plate is incubated for a period of time sufficient for binding to occur and subsequently washed with PBS to remove unbound antibody. The plate is then blocked with a PBS/BSA solution to prevent sample proteins from nonspecifically binding the microtiter plate. Test sample are subsequently added to the wells and the plate is incubated for a period of time sufficient for binding to occur. The wells are washed with PBS

to remove unbound protein. Labeled anti-ST receptor antibodies, which recognize portions of ST receptor not recognized by the first antibody, are added to the wells. The plate is incubated for a period of time sufficient for binding 5 to occur and subsequently washed with PBS to remove unbound, labeled anti-ST receptor antibody. The amount of labeled and bound anti-ST receptor antibody is subsequently determined by standard techniques.

Kits which are useful for the detection of ST receptor 10 in a test sample comprise a container comprising anti-ST receptor antibodies, in particular those which bind to the extracellular domain (amino acids 24-430) and a container or containers comprising controls. Controls include one control sample which does not contain ST receptor protein and/or 15 another control sample which contains ST receptor protein. The anti-ST receptor antibodies used in the kit are detectable such as being detectably labelled. If the detectable anti-ST antibody is not labelled, it may be detected by second antibodies or protein A for example which may also be provided 20 in some kits in separate containers. Additional components in some kits include solid support, buffer, and instructions for carrying out the assay.

The immunoassay is useful for detecting ST receptor in homogenized tissue samples and body fluid samples including 25 the plasma portion or cells in the fluid sample.

Western Blots:

The present invention relates to methods of identifying individuals suffering from colorectal cancer metastasis by detecting the presence of ST receptor protein in 30 sample of extraintestinal tissue or body fluid using Western blots. Western blots use detectable anti-ST receptor antibodies, preferably those which bind to the extracellular domain (amino acids 24-430) or C terminal tail (amino acids 1031-1093) to bind to any ST receptor present in a samples and 35 thus indicate the presence of the receptor in the sample.

The present invention also relates to methods of identifying individuals suffering from colorectal cancer using

Western blots to detect the presence of ST receptor protein in samples of tumor using antibodies which were produced in response to exposure to ST receptor protein.

Western blot techniques, which are described in 5 Sambrook, J. et al., (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, which is incorporated herein by reference, are similar to immunoassays with the essential difference being that prior to exposing the sample to the antibodies, the 10 proteins in the samples are separated by gel electrophoresis and the separated proteins are then probed with antibodies. In some preferred embodiments, the matrix is an SDS-PAGE gel matrix and the separated proteins in the matrix are transferred to a carrier such as filter paper prior to probing with 15 antibodies. Anti-ST receptor antibodies described above are useful in Western blot methods. The antibodies preferably bind to the extracellular domain of ST receptor protein. In particular, the antibodies preferably bind to amino acids 24-430 of ST receptor protein. In some embodiments, the 20 antibodies bind to the C-terminal tail of ST receptor protein, i.e. amino acids 1031-1093.

Generally, samples are homogenized and cells are lysed using detergent such as Triton-X. The material is then separated by the standard techniques in Sambrook, J. et al., 25 (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Kits which are useful for the detection of ST receptor in a test sample by Western Blot comprise a container comprising anti-ST receptor antibodies, preferably those which 30 bind to the extracellular domain (amino acids 24-430) or C terminal tail (amino acids 1031-1093), and a container or containers comprising controls. Controls include one control sample which does not contain ST receptor protein and/or another control sample which contains ST receptor protein. The 35 anti-ST receptor antibodies used in the kit are detectable such as being detectably labelled. If the detectable anti-ST antibody is not labelled, it may be detected by second

antibodies or protein A for example which may also be provided in some kits in separate containers. Additional components in some kits include instructions for carrying out the assay.

Western blots are useful for detecting ST receptor in 5 homogenized tissue samples and body fluid samples including the plasma portion or cells in the fluid sample.

ST Binding Assay:

The present invention relates to methods of identifying individuals suffering from colorectal cancer 10 metastasis by detecting presence of ST receptor protein in sample of extraintestinal tissue or body fluid using an ST receptor binding assay. The ST receptor binding assay uses a detectable ST receptor ligand to bind to any ST receptor present and thus indicate the presence of the receptor in a 15 sample.

The present invention also relates to methods of identifying individuals suffering from colorectal cancer by detecting the presence of ST receptor protein in samples of tumor.

In some embodiments, the ST receptor ligand may be native ST. Native ST isolated from *E. coli* is 18 or 19 amino acids in length. The smallest "fragment" of ST which retains activity is the 13 amino acid core peptide extending toward the carboxy terminal from cysteine 6 to cysteine 18 (of the 19 amino acid form). Analogues of ST have been generated by cloning and by chemical techniques. Small peptide fragments of the native ST structure which include the structural determinant that confers binding activity may be constructed. Once a structure is identified which binds to ST receptors, 30 non-peptide analogues mimicking that structure in space are designed. U.S. Patent Application Serial Number 08/141,892, filed October 26, 1993, which is incorporated herein by reference, describes the amino acid sequences of such compounds including derivatives thereof having substantially identical 35 amino acid sequences of ST peptides with deletions and/or insertions and/or conservative substitutions of amino acids and/or comprising D amino acids.

The ST receptor binding assay can be readily performed by those having ordinary skill in the art using readily available starting materials. ST receptor binding assays may be performed a variety of ways but each essentially identify
5 whether or not an ST receptor protein is present in a sample by determining whether or not a detectable ST receptor ligand binds to a receptor in a sample. Briefly, the assay consists of incubating a sample with a constant concentration of an ST ligand such as 1×10^{-10} M to 5×10^{-10} M of ^{125}I -ST. As a
10 control, a duplicate preparation of a sample known to contain ST receptors are incubated with a duplicate concentration of ^{125}I -ST. Assays are incubated to equilibrium (for example 2 hours) and the sample is analyzed to determine whether or not ^{125}I -ST is bound to material in the sample. The ^{125}I -ST/sample
15 is passed through a filter which is capable of allowing ^{125}I -ST to pass through but not capable of allowing ST receptor to pass through. Thus, if ST receptor is present in the sample, it will bind the ^{125}I -ST which will then be trapped by the filter. Detection of ^{125}I -ST in the filter indicates the presence of ST
20 receptor in the sample. In some preferred embodiments, the filter is Whitman GFB glass filter paper. Controls include using samples which are known to contain ST receptors, e.g. intestinal membranes from rat intestine, human intestine, T84 cells, isolated ST receptor protein or cells expressing cloned
25 nucleotide sequence encoding ST receptor proteins.

ST may be isolated from natural sources using standard techniques. Additionally, ST receptor binding peptides and conjugated compositions or portions thereof which are peptides may be prepared routinely by any of the following known
30 techniques.

In addition to being conjugated to ^{125}I , ST may be detectable by binding it to other radionuclides such as ^{43}K , ^{52}Fe , ^{57}Co , ^{67}Cu , ^{67}Ga , ^{68}Ga , ^{77}Br , $^{81}\text{Rb}/^{81\text{M}Kr}$, $^{87\text{M}Sr}$, $^{99\text{M}Tc}$, ^{111}In , $^{113\text{M}In}$, ^{123}I , ^{125}I , ^{127}Cs , ^{129}Cs , ^{131}I , ^{132}I , ^{197}Hg , ^{203}Pb and ^{206}Bi , ^{47}Sc , ^{67}Cu , ^{90}Y , ^{109}Pd , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{199}Au , ^{211}At , ^{212}Pb , ^{212}B ,
35 ^{32}P and ^{33}P , ^{71}Ge , ^{77}As , ^{103}Pb , ^{105}Rh , ^{111}Ag , ^{119}Sb , ^{121}Sn , ^{131}Cs , ^{143}Pr ,
 ^{161}Tb , ^{177}Lu , ^{191}Os , ^{193}Mpt and ^{197}Hg or by binding it to other

labels such as fluorescein or enzymes. Each of the labelling means described above for detectably labelling antibodies can be adapted to label ST receptor ligands and are considered to be described as such herein.

5 Kits include containers comprising detectable ST receptor ligand together with containers having positive and/or negative controls, i.e. samples which contain ST receptor and samples which contain no ST receptor, respectively. The detectable ST receptor ligand is preferably labelled.

10 Additional components in some kits include solid support, buffer, and instructions for carrying out the assay.

The ST receptor binding assay is useful for detecting ST receptor in homogenized tissue samples and body fluid samples including the plasma portion or cells in the fluid 15 sample.

Nucleotide Sequence based detection:

Aspects of the present invention include various methods of determining whether a sample contains cells that express ST receptor by sequence-based molecular analysis.

20 Several different methods are available for doing so including those using Polymerase Chain Reaction (PCR) technology such as PCR amplification including RT-PCR amplification, using Northern blot technology (mRNA), Southern Blot technology (cDNA), oligonucleotide hybridization technology, *in situ* 25 hybridization technology, ribonuclease protection assay (RPA), *in situ* PCR or hybridization, S1-nuclease protection assay, immune-capture RT-PCR, nucleic acid sequence-based amplification (NASBA), branched DNA (bDNA) technology, and strand-displacement amplification (SDA).

30 The invention relates to oligonucleotide probes and primers used in the methods of identifying mRNA that encodes ST receptor and to diagnostic kits which comprise such components. In preferred embodiments, the probes and primers for detecting mRNA that encodes ST receptor protein preferably hybridize to 35 nucleotide sequences that encode the extracellular domain (amino acids 24-430 encoded by nucleotides 72-1290) or the C terminal tail (amino acids 1031-1093 encoded by nucleotides

3091-3274) of ST receptor protein. Accordingly, the probes and primers for detecting mRNA that encodes ST receptor protein preferably hybridizes to nucleotide sequences within the sequence 72-1290 which is the sequence in the mRNA that encodes 5 the extracellular domain (amino acids 24-430). Alternatively, the probes and primers for detecting mRNA that encodes ST receptor protein preferably hybridizes to nucleotide sequences within the sequence 3091-3274 which is the sequence in the mRNA that encodes the C terminal tail (amino acids 1031-1093) of ST 10 receptor protein. The mRNA sequence-based methods for determining whether a sample mRNA encoding ST receptor include but are not limited to PCR amplification including RT-PCR amplification, Northern blot analysis of mRNA, Southern Blot analysis of cDNA generated from mRNA, oligonucleotide 15 hybridization (dot blots), *in situ* hybridization, ribonuclease protection assays (RPA), *in situ* PCR or hybridization assays, S1-nuclease protection assays, immune-capture RT-PCR, nucleic acid sequence-based amplification (NASBA), branched DNA (bDNA) technology, and strand-displacement amplification (SDA).

20 The nucleotide sequence encoding ST receptor protein is well known such as in F.J. Sauvage et al. 1991 *J. Biol. Chem.* 266:17912-17918. In addition to being disclosed in Sauvage et al. SUPRA, the nucleotide sequence of human ST receptor is set forth herein as SEQ ID NO:1. Reagents, such as 25 probes and primers which hybridize to mRNA or cDNA that encodes ST receptor protein, particularly reagents that hybridize to sequences within 72-1290 or 1031-1093 may be designed based upon sequence information in SEQ ID NO:1.

The methods described herein are meant to exemplify 30 how the present invention may be practiced and are not meant to limit the scope of invention. It is contemplated that other sequence-based methodology for detecting the presence of specific mRNA that encodes ST receptor in extraintestinal samples may be employed according to the invention.

35 A preferred method to detecting mRNA that encodes ST receptor in genetic material derived from extraintestinal samples uses polymerase chain reaction (PCR) technology. PCR

technology is practiced routinely by those having ordinary skill in the art and its uses in diagnostics are well known and accepted. Methods for practicing PCR technology are disclosed in "PCR Protocols: A Guide to Methods and Applications", Innis, 5 M.A., et al. Eds. Academic Press, Inc. San Diego, CA (1990) which is incorporated herein by reference. Applications of PCR technology are disclosed in "Polymerase Chain Reaction" Erlich, H.A., et al., Eds. Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) which is incorporated herein by reference. 10 U.S. Patent Number 4,683,202, U.S. Patent Number 4,683,195, U.S. Patent Number 4,965,188 and U.S. Patent Numbers 5,075,216, which are each incorporated herein by reference describe methods of performing PCR. PCR may be routinely practiced using Perkin Elmer Cetus GENE AMP RNA PCR kit, Part No. N808-15 0017.

PCR technology allows for the rapid generation of multiple copies of DNA sequences by providing 5' and 3' primers that hybridize to sequences present in an RNA or DNA molecule, and further providing free nucleotides and an enzyme which 20 fills in the complementary bases to the nucleotide sequence between the primers with the free nucleotides to produce a complementary strand of DNA. The enzyme will fill in the complementary sequences adjacent to the primers. If both the 5' primer and 3' primer hybridize to nucleotide sequences on 25 the same small fragment of nucleic acid, exponential amplification of a specific double-stranded size product results. If only a single primer hybridizes to the nucleic acid fragment, linear amplification produces single-stranded products of variable length.

30 Primers are designed based upon the nucleotide sequence encoding ST receptor protein which is described in F.J. Sauvage et al. 1991 *J. Biol. Chem.* 266:17912-17918 and SEQ ID NO:1. Preferably, primers are designed to hybridize to sequences within 72-1290 of SEQ ID NO:1. In some embodiments, 35 primers hybridize to sequences within 3091-3274 of SEQ ID NO:1. To perform this method, RNA is extracted from cells in a sample

and tested or used to make cDNA using well known methods and readily available starting materials.

The mRNA or cDNA is combined with the primers, free nucleotides and enzyme following standard PCR protocols. The 5 mixture undergoes a series of temperature changes. If the mRNA or cDNA encoding ST receptor is present, that is, if both primers hybridize to sequences on the same molecule, the molecule comprising the primers and the adjacent complementary sequences will be exponentially amplified. The amplified DNA 10 can be easily detected by a variety of well known means. If the chimeric gene is not present, no DNA molecule will be exponentially amplified. Rather, amplification of wild-type transcript will yield low levels of variable length product. The PCR technology therefore provides an extremely easy, 15 straightforward and reliable method of detecting mRNA encoding ST receptor protein in a sample.

PCR primers can be designed routinely by those having ordinary skill in the art using well known cDNA sequence information. Primers are generally 8-50 nucleotides, 20 preferably 18-28 nucleotides. A set of primers contains two primers. When performing PCR on extracted mRNA or cDNA generated therefrom, if the mRNA or cDNA encoding ST receptor protein is present, multiple copies of the mRNA or cDNA will be made. If it is not present, PCR will not generate a discrete 25 detectable product. Primers preferably hybridize to sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1. In some preferred embodiments primers selected from the group of SEQ ID NOS:3-72 are employed.

PCR product, i.e. amplified DNA, may be detected by 30 several well known means. The preferred method for detecting the presence of amplified DNA is to separate the PCR reaction material by gel electrophoresis and stain the gel with ethidium bromide in order to visualize the amplified DNA if present. A size standard of the expected size of the amplified DNA is 35 preferably run on the gel as a control.

In some instances, such as when unusually small amounts of RNA are recovered and only small amounts of cDNA are

generated therefrom, it is desirable or necessary to perform a PCR reaction on the first PCR reaction product. That is, if difficult to detect quantities of amplified DNA are produced by the first reaction, a second PCR can be performed to make 5 multiple copies of DNA sequences of the first amplified DNA. A nested set of primers are used in the second PCR reaction. The nested set of primers hybridize to sequences downstream of the 5' primer and upstream of the 3' primer used in the first reaction.

10 The present invention includes oligonucleotide which are useful as primers for performing PCR methods to amplify mRNA or cDNA that encodes ST receptor protein.

According to the invention, diagnostic kits can be assembled which are useful to practice methods of detecting the 15 presence of mRNA or cDNA that encodes ST receptor in extraintestinal samples. Such diagnostic kits comprise oligonucleotide which are useful as primers for performing PCR methods. In some preferred embodiments primers comprise sequences that hybridize to sequences within 72-1290 of SEQ ID 20 NO:1 or sequences within 3091-3274 of SEQ ID NO:1. In some preferred embodiments, primers comprise sequences selected from the group SEQ ID NOS:3-72. It is preferred that diagnostic kits according to the present invention comprise a container comprising a size marker to be run as a standard on a gel used 25 to detect the presence of amplified DNA. The size marker is the same size as the DNA generated by the primers in the presence of the mRNA or cDNA encoding ST receptor.

PCR assays are useful for detecting mRNA encoding ST receptor in homogenized tissue samples and cells in body fluid 30 samples. It is contemplated that PCR on the plasma portion of a fluid sample could be used to detect mRNA encoding ST receptor protein.

Another method of determining whether a sample contains cells expressing ST receptor is by Northern Blot 35 analysis of mRNA extracted from an extraintestinal sample. The techniques for performing Northern blot analyses are well known by those having ordinary skill in the art and are described in

Sambrook, J. et al., (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. mRNA extraction, electrophoretic separation of the mRNA, blotting, probe preparation and hybridization are all 5 well known techniques that can be routinely performed using readily available starting material.

One having ordinary skill in the art, performing routine techniques, could design probes to identify mRNA encoding ST receptor using the information in F.J. Sauvage et 10 al. 1991 *J. Biol. Chem.* 266:17912-17918. The sequence for human ST receptor is also disclosed in SEQ ID NO:1. In some preferred embodiments probes comprise sequences that hybridize to sequences within 1-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1.

15 The mRNA is extracted using poly dT columns and the material is separated by electrophoresis and, for example, transferred to nitrocellulose paper. Labelled probes made from an isolated specific fragment or fragments can be used to visualize the presence of a complementary fragment fixed to the 20 paper.

According to the invention, diagnostic kits can be assembled which are useful to practice methods of detecting the presence of mRNA that encodes ST receptor in extraintestinal samples by Northern blot analysis. Such diagnostic kits 25 comprise oligonucleotide which are useful as probes for hybridizing to the mRNA. The probes may be radiolabelled. In some preferred embodiments probes comprise sequences that hybridize to sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1. It is preferred 30 that diagnostic kits according to the present invention comprise a container comprising a size marker to be run as a standard on a gel. It is preferred that diagnostic kits according to the present invention comprise a container comprising a positive control which will hybridize to the 35 probe.

Northern blot analysis is useful for detecting mRNA encoding ST receptor in homogenized tissue samples and cells in

body fluid samples. It is contemplated that PCR on the plasma portion of a fluid sample could be used to detect mRNA encoding ST receptor protein.

Another method of detecting the presence of mRNA encoding ST receptor protein by oligonucleotide hybridization technology. Oligonucleotide hybridization technology is well known to those having ordinary skill in the art. Briefly, detectable probes which contain a specific nucleotide sequence that will hybridize to nucleotide sequence of mRNA encoding ST receptor protein. RNA or cDNA made from RNA from a sample is fixed, usually to filter paper or the like. The probes are added and maintained under conditions that permit hybridization only if the probes fully complement the fixed genetic material. The conditions are sufficiently stringent to wash off probes in which only a portion of the probe hybridizes to the fixed material. Detection of the probe on the washed filter indicates complementary sequences. One having ordinary skill in the art, using the sequence information disclosed in F.J. Sauvage et al. 1991 *J. Biol. Chem.* 266:17912-17918 and SEQ ID NO:1 can design probes which are fully complementary to mRNA sequences but not genomic DNA sequences. In some preferred embodiments probes comprise sequences that hybridize to sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1. Hybridization conditions can be routinely optimized to minimize background signal by non-fully complementary hybridization.

The present invention includes labelled oligonucleotide which are useful as probes for performing oligonucleotide hybridization. That is, they are fully complementary with mRNA sequences but not genomic sequences. For example, the mRNA sequence includes portions encoded by different exons. The labelled probes of the present invention are labelled with radiolabelled nucleotides or are otherwise detectable by readily available nonradioactive detection systems.

According to the invention, diagnostic kits can be assembled which are useful to practice oligonucleotide

hybridization methods of the invention. Such diagnostic kits comprise a labelled oligonucleotide which encodes portions of ST receptor encoded by different exons. In some preferred embodiments probes comprise sequences that hybridize to 5 sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1. It is preferred that labelled probes of the oligonucleotide diagnostic kits according to the present invention are labelled with a radionucleotide. The oligonucleotide hybridization-based diagnostic kits according 10 to the invention preferably comprise DNA samples that represent positive and negative controls. A positive control DNA sample is one that comprises a nucleic acid molecule which has a nucleotide sequence that is fully complementary to the probes of the kit such that the probes will hybridize to the molecule 15 under assay conditions. A negative control DNA sample is one that comprises at least one nucleic acid molecule, the nucleotide sequence of which is partially complementary to the sequences of the probe of the kit. Under assay conditions, the probe will not hybridize to the negative control DNA sample.

20 Oligonucleotide hybridization techniques are useful for detecting mRNA encoding ST receptor in homogenized tissue samples and cells in body fluid samples. It is contemplated that PCR on the plasma portion of a fluid sample could be used to detect mRNA encoding ST receptor protein.

25 **Tissue Analysis:**

Another aspect of the invention relates to methods of analyzing tissue samples which are fixed sections routinely prepared by surgical pathologists to characterize and evaluate cells. In some embodiments, the cells are from laminapropria 30 and are analyzed to determine and evaluate the extent of metastasis of colorectal tumor cells. The laminapropria represents the barrier between the intestinal or colorectal track and the rest of the body. By identifying the presence of ST receptor or mRNA that encodes ST receptor protein in cells 35 of the laminapropria, the extent of invasion/infiltration of colorectal tumor cells into extraintestinal tissue can be evaluated. In some embodiments, the cells are removed in a

biopsy or as an adenocarcinoma of unknown origin and are analyzed to determine and evaluate whether they are colorectal tumor cells.

The present invention relates to *in vitro* kits for evaluating tissue samples to determine the level of metastasis and to reagents and compositions useful to practice the same. In some embodiments of the invention, tissue samples that include portions of the laminapropria may be isolated from individuals undergoing or recovering from surgery to remove colorectal tumors include resection or colonoscopy. The tissue is analyzed to identify the presence or absence of the ST receptor protein. Techniques such as an ST receptor/ligand binding assay and immunohistochemistry assay may be performed to determine whether the ST receptor is present in cells in the tissue sample which are indicative of metastatic migration. As discussed above, preferred immunoassays for identifying the presence of ST receptor protein use antibodies that bind to epitopes on ST receptor protein which comprise amino acids 24-430 or 1031-1093. Accordingly, in aspects of the invention which relate to immunohistochemistry assays and kits and reagents for performing the same, such extracellular domain-specific or C terminal tail-specific antibodies are preferred. Alternatively, in some embodiments of the invention, tissue samples are analyzed to identify whether ST receptor protein is being expressed in cells in the tissue sample which indicate metastatic migration by detecting the presence or absence of mRNA that encodes the ST receptor protein. The presence of mRNA that encodes the ST receptor protein or cDNA generated therefrom can be determined using techniques such as *in situ* hybridization and *in situ* PCR assays. The probes and primers used in *in situ* hybridization and *in situ* PCR assays preferably hybridize to sequence that encode amino acids 24-430 or amino acids 1031-1093 of ST receptor protein. Accordingly, in some preferred embodiments, probes comprise sequences that hybridize to sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1.

The present invention relates to *in vitro* kits for evaluating samples of tumors to determine whether or not they are colorectal in origin and to reagents and compositions useful to practice the same. In some embodiments of the invention, tumor samples may be isolated from individuals undergoing or recovering from surgery to remove tumors in the colon, tumors in other organs or biopsy material. The tumor sample is analyzed to identify the presence or absence of the ST receptor protein. Techniques such as an ST receptor/ligand binding assays and immunohistochemistry assays may be performed to determine whether the ST receptor is present in cells in the tumor sample which are indicative of colorectal origin. In some preferred embodiments of the invention which relate to immunohistochemistry assays and kits and reagents for performing the same, extracellular domain-specific antibodies (i.e. those which bind to epitopes on ST receptor protein which comprise amino acids 24-430) or C terminal tail-specific antibodies (amino acids 1031-1093) are preferred. Alternatively, in some embodiments of the invention, lumen tissue samples are analyzed to identify whether ST receptor protein is being expressed in cells in the tumor sample which indicate colorectal origin by detecting the presence or absence of mRNA that encodes the ST receptor protein. The presence of mRNA that encodes the ST receptor protein or cDNA generated therefrom can be determined using techniques such as *in situ* hybridization and *in situ* PCR assays. The probes and primers used in *in situ* hybridization and *in situ* PCR assays preferably hybridize to sequence that encode amino acids 24-430 or amino acids 1031-1093 of ST receptor protein. Accordingly, in some preferred embodiments, probes comprise sequences that hybridize to sequences within 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1.

In situ hybridization technology is well known by those having ordinary skill in the art. Briefly, cells are fixed and detectable probes which contain a specific nucleotide sequence are added to the fixed cells. If the cells contain complementary nucleotide sequences, the probes, which can be

detected, will hybridize to them. One having ordinary skill in the art, using the sequence information in F.J. Sauvage et al. 1991 *J. Biol. Chem.* 266:17912-17918 and SEQ ID NO:1, can design probes useful in *in situ* hybridization technology to identify 5 cells that express ST receptor. The probes used to detect in *in situ* hybridization preferably hybridize to sequence that encode amino acids 24-430 or amino acids 1031-1093 of ST receptor protein. Accordingly, in some preferred embodiments, probes comprise sequences that hybridize to sequences within 10 72-1290 of SEQ ID NO:1 or sequences within 3091-3274 of SEQ ID NO:1.

The probes are fully complementary and do not hybridize well to partially complementary sequences. For *in situ* hybridization according to the invention, it is preferred 15 that the probes are detectable by fluorescence. A common procedure is to label probe with biotin-modified nucleotide and then detect with fluorescently tagged avidin. Hence, probe does not itself have to be labelled with fluorescent but can be subsequently detected with fluorescent marker.

20 Cells are fixed and the probes are added to the genetic material. Probes will hybridize to the complementary nucleic acid sequences present in the sample. Using a fluorescent microscope, the probes can be visualized by their fluorescent markers.

25 According to the invention, diagnostic kits can be assembled which are useful to practice *in situ* hybridization methods of the invention are fully complementary with mRNA sequences. It is preferred that labelled probes of the *in situ* diagnostic kits according to the present invention are labelled 30 with a fluorescent marker.

Those having ordinary skill in the art can analyze the fixed cells to characterize the level of metastatic migration of the colon cancer cells. The labelling of colon-derived cells allows for improved analysis.

35 Immunohistochemistry techniques may be used to identify and essentially stain cells with ST receptor. Such "staining" allows for analysis of metastatic migration. Anti-

ST receptor antibodies such as those described above of contacted with fixed cells and the ST receptor present in the cells reacts with the antibodies. The antibodies are detectably labelled or detected using labelled second antibody 5 or protein A to stain the cells. In some preferred embodiments of the invention which relate to immunohistochemistry assays and kits and reagents for performing the same, extracellular domain-specific antibodies (i.e. those which bind to epitopes on ST receptor protein which comprise amino acids 72-430) or C 10 terminal tail-specific antibodies (i.e. those which bind to epitopes on ST receptor protein which comprise amino acids 1031-1093) are preferred.

ST binding assays may be performed instead of immunohistochemistry except that the cell section is first 15 frozen, then the ST binding assay is performed and then the cells are fixed.

The techniques described herein for evaluating tumor sections can also be used to analyze tissue sections for samples of lymph nodes as well as other tissues to identify the 20 presence of colorectal tumor cells. The samples can be prepared and "stained" to detect expression of ST receptor.

EXAMPLE

ST receptor is a highly specific marker for metastatic colorectal cancer. The sequence of the human homologue of this 25 protein has been defined and is shown in SEQ ID NO:1 and SEQ ID NO:2. Two human sequences have been defined, differing in only 2 amino acids in their extracellular binding domains. The differences include a conservative substitution of C₁₀₃₈ and substitution of C₁₀₃₉ to G₁₀₃₉ with an associate conservative 30 substitution of leu to val. The expression of ST receptor exclusively by metastatic colorectal cells, compared to other extraintestinal cells and tumors, permits detection of the presence of these cells in samples of tissues and body fluids by testing for the presence of the nucleic acids encoding this 35 protein. Specifically, the presence of colorectal cancer cells expressing this marker can be detected by examining specimens for the presence of the ST receptor protein itself or the mRNA

encoding this protein. This mRNA can be detected by a number of techniques involving the recognition and amplification of sequences in this mRNA which are unique for this protein compared to other proteins of this family or in general. For example, primers or oligonucleotides derived from specific sequences complimentary to the mRNA that encodes ST receptor can be used to detect the expression of this protein by PCR, RT-PCR, Northern blot analysis, RPA, *in situ* PCR or hybridization, S1-nuclease protection assay, immune-capture RT-PCR, nucleic acid sequence-based amplification (NASBA), branched DNA (bDNA) technology, and strand-displacement amplification (SDA).

According to some aspects of the invention, a key feature is the utility of specific sequences derived from specific sections of the DNA encoding this protein as probes for these techniques. Previous studies suggested that although ST receptor protein was primarily expressed in intestinal cells, there might be expression in other tissues as well, such as, for example, in brain and adrenal. However, the probes used in those studies for PCR or cDNA cloning were derived from the carboxy terminal domain of this protein. This domain shares significant sequence homology with almost all members of the family of particulate receptor guanylyl cyclases, of which there are currently 8 known members. In addition, comparing the probes used in those studies with existing gene data banks of known proteins demonstrated that the probes used in those earlier studies exhibited sufficient sequence homology to hybridize with >50 eukaryotic and prokaryotic proteins. In contrast, the extracellular domain of ST receptor protein (amino acids 24-430; nucleotides 72-1290) exhibits little sequence homology with other members of the guanylyl cyclase family (<10%) and no homology with other proteins. Thus, probes to examine the specific expression of ST receptor protein in tissues should ideally be derived from this unique region of the protein.

Recently, the expression of ST receptor protein in human tissues and tumors was examined employing cDNA probes

complimentary to regions of the extracellular domain by RT-PCR and RNAase protection and compared these results to those employing probes used in earlier studies in which it was suggested that ST receptor protein might be expressed in other 5 tissues. Indeed, using cDNA primers derived from the extracellular domain, the ST receptor protein was found to be expressed only in intestinal epithelial cells and colorectal cancer cells, but not in any other extraintestinal tissue or tumor, including brain and adrenal. In contrast, when the 10 primers derived from the cytoplasmic domain of this protein were employed in the same RT-PCR experiments, complimentary mRNA was found in brain and adrenal, as demonstrated previously in other studies. These data, in which the unique extracellular domain is undetectable by PCR but the highly 15 homologous cytoplasmic domain is detectable, in brain and adrenal, demonstrates that GCC is uniquely expressed only in intestinal epithelium cells and colorectal cancer cells but not in other extraintestinal tissues or tumors. In contrast, the 20 PCR product detected in brain and adrenal employing primers derived from the cytoplasmic domain of ST receptor protein likely reflects a new member of the family of receptor guanylyl 25 cyclases with homologous cytoplasmic domains.

These data demonstrate that the highest specificity for diagnostic tests employing ST receptor protein as a marker 25 can be obtained with nucleotide sequences as test probes which are derived from the extracellular domain. Employing primers derived from the extracellular domain of ST receptor protein is a key feature of the diagnostic tests being developed for colorectal cancer.

30 A series of primers have been identified which are complimentary to various regions of the extracellular domain of human ST receptor protein . These primers were selected based on criteria of 100% specificity for the nucleotide sequence of interest (uniqueness for ST receptor protein) and optimization 35 of hybridization compatibility (minimize non-specific interactions and avoid significant secondary structure that may not permit hybridization). The utility of these sequences for

identifying and amplifying ST receptor protein were confirmed by computer-based algorithms.

Primers are shown as SEQ ID NOS:3-72. Specific primer pairs include SEQ ID NO:3 and SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38, SEQ ID NO:39 and SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:56, SEQ ID NO:57 and SEQ ID NO:58, SEQ ID NO:59 and SEQ ID NO:60, SEQ ID NO:61 and SEQ ID NO:62, SEQ ID NO:63 and SEQ ID NO:64, SEQ ID NO:65 and SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68, SEQ ID NO:69 and SEQ ID NO:70, and SEQ ID NO:71 and SEQ ID NO:72.

The primers with odd numbered sequence identification numbers of SEQ ID NOS:3-72 (i.e. SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, etc.) can be matched with any of primers with even numbered sequence identification numbers of SEQ ID NOS:3-72 (i.e. SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, etc.) provided the pairing can be used to amplify a product from a template having SEQ ID NO:1. Those having ordinary skill in the art can readily identify which of the primers with odd numbered sequence identification numbers can be paired with which of primers with even numbered sequence identification numbers. For example, primers with odd numbered sequence identification numbers of SEQ ID NOS:3-49 SEQ ID NO:67 and SEQ ID NO:69 can be paired with any of primers with even numbered sequence identification numbers of SEQ ID NOS:3-72. Similarly, primers with SEQ ID NO:51, SEQ ID NO:63 and SEQ ID NO:65 can be paired with primers with SEQ ID NO:26, SEQ ID NO:32, SEQ ID NO:36, SEQ

ID NO:46, even numbered sequence identification numbers of SEQ ID NOs:52-66 and SEQ ID NO:72. Primers with odd numbered sequence identification numbers SEQ ID NOs:53-57 can be paired with primers with even numbered sequence identification numbers of SEQ ID NOs:52-66 and SEQ ID NO:72. Primers with sequence identification numbers SEQ ID NO:59 and SEQ ID NO:61 can be paired with primers with even numbered sequence identification numbers of SEQ ID NOs:52-62 and SEQ ID NO:72. Primers with SEQ ID NO:71 can be paired with primers with SEQ ID NO:26, SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:46, even numbered sequence identification numbers of SEQ ID NOs:50-66 and SEQ ID NO:72.

Based on this selection, primers optimal for specific and sensitive detection of human ST receptor protein have been identified. These sequences are not only unique, highly specific, and cross-compatible, they are also free of non-specific dimer formation, secondary structures, and sequence repeats. PCR-generated hybridization probes generated with these primers will be exquisitely specific for signal-based amplification systems to detect expression of ST receptor protein, such as Northern analysis, ligase chain reaction (LCR), Q-beta replicase (QBR) assay, and bDNA. Various combinations of these primers have been successfully employed to specifically detect the expression of ST receptor protein in colorectal tumors in tissues and blood, compared to other extraintestinal tissues and tumors.

Alternate short sequence-specific antisense reverse transcription primers for amplification of the unique extracellular ligand binding domain of ST receptor protein may include SEQ ID NO:73 and/or SEQ ID NO:74.

This transmembrane domain of the human ST-receptor (hSTR) is 100% homologous between the hST-r sequences submitted to GENEBANK and EMBL. A series of 12-15 nucleotide antisense primers are generated from this sequence. Reverse transcription (RT) appears to be more specific and efficient using any of these short antisense RT-primers (Pfeffer U, Fecarotta E, Vidali G. (1995) Biotechniques 18:204-206 which is incorporated herein by reference). Indeed, multiplex short

sequence-specific reverse transcription primers enhance specificity, due to the unique highly specific sequences selected, and their length prevents interference in subsequent amplification steps, due to their low melting temperatures.

- 5 PCR and nested-PCR can then be used to identify any human ST-receptor sequences. This process is an alternative to employing the primers for RT-PCR described above.

SEQUENCE LISTING

SEQ ID NO:1

SEQ ID:1

-77

tggagtggc tgagggactc cactagaggc tgtccatctg gattccctgc ctcccttagga
gcccaacaga gcaaagcaag tgggcacaag gagtatggtt ctaacgtat tgggtc

1/1

31/11

ATG AAG ACG TTG CTG TTG GAC TTG GCT TTG TGG TCA CTG CTC TTC CAG CCC GGG TGG CTG
Met lys thr leu leu leu asp leu ala leu trp ser leu leu phe gln pro gly trp leu

61/21

91/31

TCC TTT AGT TCC CAG GTG AGT CAG AAC TGC CAC AAT GGC AGC TAT GAA ATC AGC GTC CTG
ser phe ser ser gln val ser gln asn cys his asn gly ser tyr glu ile ser val leu

121/41

151/51

ATG ATG GGC AAC TCA GCC TTT GCA GAG CCC CTG AAA AAC TTG GAA GAT GCG GTG AAT GAG
met met gly asn ser ala phe ala glu pro leu lys asn leu glu asp ala val asn glu

181/61

211/71

GGG CTG GAA ATA GTG AGA GGA CGT CTG CAA AAT GCT GGC CTA AAT GTG ACT GTG AAC GCT
gly leu ile val arg gly arg leu gln asn ala gly leu asn val thr val asn ala

241/81

271/91

ACT TTC ATG TAT TCG GAT GGT CTG ATT CAT AAC TCA GGC GAC TGC CGG AGT AGC ACC TGT
thr phe met tyr ser asp gly leu ile his asn ser gly asp cys arg ser ser thr cys

301/101

331/111

GAA GGC CTC GAC CTA CTC AGG AAA ATT TCA AAT GCA CAA CGG ATG GGC TGT GTC CTC ATA
glu gly leu asp leu leu arg lys ile ser asn ala gln arg met gly cys val leu ile

361/121

391/131

GGG CCC TCA TGT ACA TAC TCC ACC TTC CAG ATG TAC CTT GAC ACA GAA TTG AGC TAC CCC
gly pro ser cys thr tyr ser thr phe gln met tyr leu asp thr glu leu ser tyr pro

421/141

451/151

ATG ATC TCA GCT GGA AGT TTT GGA TTG TCA TGT GAC TAT AAA GAA ACC TTA ACC AGG CTG
met ile ser ala gly ser phe gly leu ser cys asp tyr lys glu thr leu thr arg leu

481/161

511/171

ATG TCT CCA GCT AGA AAG TTG ATG TAC TTC TTG GTT AAC TTT TGG AAA ACC AAC GAT CTG
met ser pro ala arg lys leu met tyr phe leu val asn phe trp lys thr asn asp leu

541/181

571/191

CCC TTC AAA ACT TAT TCC TGG AGC ACT TCG TAT GTT TAC AAG AAT GGT ACA GAA ACT GAG
pro phe lys thr tyr ser trp ser thr ser tyr val tyr lys asn gly thr glu thr glu

601/201

631/211

GAC TGT TTC TGG TAC CTT AAT GCT CTG GAG GCT AGC GTT TCC TAT TTC TCC CAC GAA CTC
asp cys phe trp tyr leu asn ala leu glu ala ser val ser tyr phe ser his glu leu

661/221

691/231

GGC TTT AAG GTG GTG TTA AGA CAA GAT AAG GAG TTT CAG GAT ATC TTA ATG GAC CAC AAC
gly phe lys val val leu arg gln asp lys glu phe gln asp ile leu met asp his asn

721/241

751/251

AGG AAA AGC AAT GTG ATT ATT ATG TGT GGT CCA GAG TTC CTC TAC AAG CTG AAG GGT
arg lys ser asn val ile ile met cys gly gly pro glu phe leu tyr lys leu lys gly

781/261

811/271

GAC CGA GCA GTG GCT GAA GAC ATT GTC ATT ATT CTA GTG GAT CTT TTC AAT GAC CAG TAC
asp arg ala val ala glu asp ile val ile leu val asp leu phe asn asp gln tyr

841/281

871/291

TTG GAG GAC AAT GTC ACA GCC CCT GAC TAT ATG AAA AAT GTC CTT GTT CTG ACG CTG TCT

leu glu asp asn val thr ala pro asp tyr met lys asn val leu val leu thr leu ser
901/301 931/311
CCT GGG AAT TCC CTT CTA AAT AGC TCT TTC TCC AGG AAT CTA TCA CCA ACA AAA CGA GAC
pro gly asn ser leu leu asn ser ser phe ser arg asn leu ser pro thr lys arg asp

961/321 991/331
TTT CGT CTT GCC TAT TTG AAT GGA ATC CTC GTC TTT GGA CAT ATG CTG AAG ATA TTT CTT
phe arg leu ala tyr leu asn gly ile leu val phe gly his met leu lys ile phe leu

1021/341 1051/351
GAA AAT GGA GAA AAT ATT ACC ACC CCC AAA TTT GCT CAT GCC TTC AGG AAT CTC ACT TTT
glu asn gly glu asn ile thr thr pro lys phe ala his ala phe arg asn leu thr phe

1081/361 1111/371
GAA GGG TAT GAC GGT CCA GTG ACC TTG GAT GAC TGG GGG GAT GTT GAC AGT ACC ATG GTG
glu gly tyr asp gly pro val thr leu asp asp trp gly asp val asp ser thr met val

1141/381 1171/391
CTT CTG TAT ACC TCT GTG GAC ACC AAG AAA TAC AAG GTT CTT TTG ACC TAT GAT ACC CAC
leu leu tyr thr ser val asp thr lys tyr lys val leu leu thr tyr asp thr his

1201/401 1231/411
GTA AAT AAG ACC TAT CCT GTG GAT ATG AGC CCC ACA TTC ACT TGG AAG AAC TCT AAA CTT
val asn lys thr tyr pro val asp met ser pro thr phe thr trp lys asn ser lys leu

1261/421 1291/431
CCT AAT GAT ATT ACA GGC CGG GGC CCT CAG ATC CTG ATG ATT GCA GTC TTC ACC CTC ACT
pro asn asp ile thr gly arg gly pro gln ile leu met ile ala val phe thr leu thr

1321/441 1351/451
GGA GCT GTG GTG CTG CTC CTG CTC GCT CTC CTG ATG CTC AGA AAA TAT AGA AAA GAT
gly ala val val leu leu leu leu val ala leu leu met leu arg lys tyr arg lys asp

1381/461 1411/471
TAT GAA CTT CGT CAG AAA AAA TGG TCC CAC ATT CCT CCT GAA AAT ATC TTT CCT CTG GAG
tyr glu leu arg gln lys lys trp ser his ile pro pro glu asn ile phe pro leu glu

1441/481 1471/491
ACC AAT GAG ACC AAT CAT GTT AGC CTC AAG ATC GAT GAT GAC AAA AGA CGA GAT ACA ATC
thr asn glu thr asn his val ser leu lys ile asp asp lys arg arg asp thr ile

1501/501 1531/511
CAG AGA CTA CGA CAG TGC AAA TAC GTC AAA AAG CGA GTG ATT CTC AAA GAT CTC AAG CAC
gln arg leu arg gln cys lys tyr val lys lys arg val ile leu lys asp leu lys his

1561/521 1591/531
AAT GAT GGT AAT TTC ACT GAA AAA CAG AAG ATA GAA TTG AAC AAG TTG CTT CAG ATT GAC
asn asp gly asn phe thr glu lys gln lys ile glu leu asn lys leu leu gln ile asp

1621/541 1651/551
TAT TAC ACC CTA ACC AAG TTC TAC GGG ACA GTG AAA CTG GAT ACC ATG ATC TTC GGG GTG
tyr tyr thr leu thr lys phe tyr gly thr val lys leu asp thr met ile phe gly val

1681/561 1711/571
ATA GAA TAC TGT GAG AGA GGA TCC CTC CGG GAA GTT TTA AAT GAC ACA ATT TCC TAC CCT
ile glu tyr cys glu arg gly ser leu arg glu val leu asn asp thr ile ser tyr pro

1741/581 1771/591
GAT GGC ACA TTC ATG GAT TGG GAG TTT AAG ATC TCT GTC TTG TAT GAC ATT GCT AAG GGA
asp gly thr phe met asp trp glu phe lys ile ser val leu tyr asp ile ala lys gly

1801/601 1831/611
ATG TCA TAT CTG CAC TCC AGT AAG ACA GAA GTC CAT GGT CGT CTG AAA TCT ACC AAC TGC
met ser tyr leu his ser ser lys thr glu val his gly arg leu lys ser thr asn cys

1861/621 1891/631
 GTA GTG GAC AGT AGA ATG GTG GTG AAG ATC ACT GAT TTT GGC TGC AAT TCC ATT TTG CCT
 val val asp ser arg met val val lys ile thr asp phe gly cys asn ser ile leu pro

1921/641 1951/651
 CCA AAA AAG GAC CTG TGG ACA GCT CCA GAG CAC CTC CGC CAA GCC AAC ATC TCT CAG AAA
 pro lys lys asp leu trp thr ala pro glu his leu arg gln ala asn ile ser gln lys

1981/661 2011/671
 GGA GAT GTG TAC AGC TAT GGG ATC ATC GCA CAG GAG ATC ATT CTG CGG AAA GAA ACC TTC
 gly asp val tyr ser tyr gly ile ile ala gln glu ile ile leu arg lys glu thr phe

2041/681 2071/691
 TAC ACT TTG AGC TGT CGG GAC CGG AAT GAG AAG ATT TTC AGA GTG GAA AAT TCC AAT GGA
 tyr thr leu ser cys arg asp arg asn glu lys ile phe arg val glu asn ser asn gly

2101/701 2131/711
 ATG AAA CCC TTC CGC CCA GAT TTA TTC TTG GAA ACA GCA GAG AAA GAG CTA GAA GTG
 met lys pro phe arg pro asp leu phe leu glu thr ala glu glu lys glu leu glu val

2161/721 2191/731
 TAC CTA CTT GTA AAA AAC TGT TGG GAG GAA GAT CCA GAA AAG AGA CCA GAT TTC AAA AAA
 tyr leu leu val lys asn cys trp glu glu asp pro glu lys arg pro asp phe lys lys

2221/741 2251/751
 ATT GAG ACT ACA CTT GCC AAG ATA TTT GGA CTT TTT CAT GAC CAA AAA AAT GAA AGC TAT
 ile glu thr thr leu ala lys ile phe gly leu phe his asp gln lys asn glu ser tyr

2281/761 2311/771
 ATG GAT ACC TTG ATC CGA CGT CTA CAG CTA TAT TCT CGA AAC CTG GAA CAT CTG GTA GAG
 met asp thr leu ile arg arg leu gln leu tyr ser arg asn leu glu his leu val glu

2341/781 2371/791
 GAA AGG ACA CAG CTG TAC AAG GCA GAG AGG GAC AGG GCT GAC AGA CTT AAC TTT ATG TTG
 glu arg thr gln leu tyr lys ala glu arg asp arg ala asp arg leu asn phe met leu

2401/801 2431/811
 CTT CCA AGG CTA GTG GTA AAG TCT CTG AAG GAG AAA GGC TTT GTG GAG CCG GAA CTA TAT
 leu pro arg leu val val lys ser leu lys glu lys gly phe val glu pro glu leu tyr

2461/821 2491/831
 GAG GAA GTT ACA ATC TAC TTC AGT GAC ATT GTA GGT TTC ACT ACT ATC TGC AAA TAC AGC
 glu glu val thr ile tyr phe ser asp ile val gly phe thr thr ile cys lys tyr ser

2521/841 2551/851
 ACC CCC ATG GAA GTG GTG GAC ATG CTT AAT GAC ATC TAT AAG AGT TTT GAC CAC ATT GTT
 thr pro met glu val val asp met leu asn asp ile tyr lys ser phe asp his ile val

2581/861 2611/871
 GAT CAT CAT GAT GTC TAC AAG GTG GAA ACC ATC GGT GAT GCG TAC ATG GTG GCT AGT GGT
 asp his his asp val tyr lys val glu thr ile gly asp ala tyr met val ala ser gly

2641/881 2671/891
 TTG CCT AAG AGA AAT GGC AAT CGG CAT GCA ATA GAC ATT GCC AAG ATG GCC TTG GAA ATC
 leu pro lys arg asn gly asn arg his ala ile asp ile ala lys met ala leu glu ile

2701/901 2731/911
 CTC AGC TTC ATG GGG ACC TTT GAG CTG GAG CAT CTT CCT GGC CTC CCA ATA TGG ATT CGC
 leu ser phe met gly thr phe glu leu glu his leu pro gly leu pro ile trp ile arg

2761/921 2791/931
 ATT GGA GTT CAC TCT GGT CCC TGT GCT GGT GGA GTT GTG GGA ATC AAG ATG CCT CGT TAT
 ile gly val his ser gly pro cys ala ala gly val val gly ile lys met pro arg tyr

2821/941 2851/951
 TGT CTA TTT GGA GAT ACG GTC AAC ACA GCC TCT AGG ATG GAA TCC ACT GGC CTC CCT TTG
 cys leu phe gly asp thr val asn thr ala ser arg met glu ser thr gly leu pro leu

2881/961

2911/971
AGA ATT CAC GTG AGT GGC TCC ACC ATA GCC ATC CTG AAG AGA ACT GAG TGC CAG TTC CTT
arg ile his val ser gly ser thr ile ala ile leu lys arg thr glu cys gln phe leu

2941/981

2971/991
TAT GAA GTG AGA GGA ACA TAC TTA AAG GGA AGA GGA AAT GAG ACT ACC TAC TGG CTG
tyr glu val arg gly glu thr tyr leu lys gly arg asn glu thr thr tyr trp leu

3001/1001

3031/1011
ACT GGG ATG AAG GAC CAG AAA TTC AAC CTG CCA ACC CCT CCT ACT GTG GAG AAT CAA CAG
thr gly met lys asp gln lys phe asn leu pro thr pro pro thr val glu asn gln gln

3061/1021

3091/1031
CGT TTG CAA GCA GAA TTT TCA GAC ATG ATT GCC AAC TCT TTA CAG AAA AGA CAG GCA GCA
arg leu qln ala glu phe ser asp met ile ala asn ser leu qln lys arg qln ala ala

3121/1041

3151/1051
GGG ATA AGA AGC CAA AAA CCC AGA CGG GTA GCC AGC TAT AAA AAA GGC ACT CTG GAA TAC
gly ile arg ser qln lys pro arg arq val ala ser tyr lys lys qly thr leu glu tyr

3181/1061

3211/1071
TTG CAG CTG AAT ACC ACA GAC AAG GAG AGC ACC TAT TTT TAA ACC TAA ATG AGG TAT AAG
leu qln leu asn thr thr asp lys glu ser thr tyr phe

3241

3271
GAC TCA CAC AAA TTA AAA TAC AGC TGC ACT GAG GCC AGG CAC CCT CAG GTG TCC TGA AAG

3301

3331
CTT ACT TTC CTG AGA CCT CAT GAG GCA GAA ATG TCT TAG GCT TGG CTG CCC TGT TTG GAC

3361

3391
CAT GGA CTT TCT TTG CAT GAA TCA GAT GTG TTC TCA GTG AAA TAA CTA CCT TCC ACT CTG

3421

3451
GAA CCT TAT TCC AGC AGT TGT TCC AGG GAG CTT CTA CCT GGA AAA GAA AAG AAT TTC ATT

3481

3511
TAT TTT TTG TTT GTT TAT TTT TAT CGT TTT TGT TTA CTG GCT TTC CTT CTG TAT TCA TAA

3541

3571
GAT TTT TTA AAT TGT CAT AAT TAT ATT TTA AAT ACC CAT CTT CAT TAA AGT ATA TTT AAC

3601

3631
TCA TAA TTT TTG CAG AAA ATA TGC TAT ATA TTA GGC AAG AAT AAA AGC TAA AGG TTT CCC

3661
AAA AAA AAA

SEQ ID NO:2

1
Met lys thr leu leu leu asp leu ala leu trp ser leu leu phe gln pro gly trp leu
61/21 91/31

ser phe ser ser gln val ser gln asn cys his asn gly ser tyr glu ile ser val leu

- 50 -

121/41 151/51
met met gly asn ser ala phe ala glu pro leu lys asn leu glu asp ala val asn glu
181/61 211/71
gly leu glu ile val arg gly arg leu gln asn ala gly leu asn val thr val asn ala
241/81 271/91
thr phe met tyr ser asp gly leu ile his asn ser gly asp cys arg ser ser thr cys
301/101 331/111
glu gly leu asp leu leu arg lys ile ser asn ala gln arg met gly cys val leu ile
361/121 391/131
gly pro ser cys thr tyr ser thr phe gln met tyr leu asp thr glu leu ser tyr pro
421/141 451/151
met ile ser ala gly ser phe gly leu ser cys asp tyr lys glu thr leu thr arg leu
481/161 511/171
met ser pro ala arg lys leu met tyr phe leu val asn phe trp lys thr asn asp leu
541/181 571/191
pro phe lys thr tyr ser trp ser thr ser tyr val tyr lys asn gly thr glu thr glu
601/201 631/211
asp cys phe trp tyr leu asn ala leu glu ala ser val ser tyr phe ser his glu leu
661/221 691/231
gly phe lys val val leu arg gln asp lys glu phe gln asp ile leu met asp his asn
721/241 751/251
arg lys ser asn val ile ile met cys gly gly pro glu phe leu tyr lys leu lys gly
781/261 811/271
asp arg ala val ala glu asp ile val ile ile leu val asp leu phe asn asp gln tyr
841/281 871/291
leu glu asp asn val thr ala pro asp tyr met lys asn val leu val leu thr leu ser
901/301 931/311
pro gly asn ser leu leu asn ser ser phe ser arg asn leu ser pro thr lys arg asp
961/321 991/331
phe arg leu ala tyr leu asn gly ile leu val phe gly his met leu lys ile phe leu
1021/341 1051/351
glu asn gly glu asn ile thr thr pro lys phe ala his ala phe arg asn leu thr phe
1081/361 1111/371
glu gly tyr asp gly pro val thr leu asp asp trp gly asp val asp ser thr met val

1141/381

1171/391

leu leu tyr thr ser val asp thr lys lys tyr lys val leu leu thr tyr asp thr his

1201/401

1231/411

val asn lys thr tyr pro val asp met ser pro thr phe thr trp lys asn ser lys leu

1261/421

1291/431

pro asn asp ile thr gly arg gly pro gln ile leu met ile ala val phe thr leu thr

1321/441

1351/451

gly ala val val leu leu leu leu val ala leu leu met leu arg lys tyr arg lys asp

1381/461

1411/471

tyr glu leu arg gln lys lys trp ser his ile pro pro glu asn ile phe pro leu glu

1441/481

1471/491

thr asn glu thr asn his val ser leu lys ile asp asp asp lys arg arg asp thr ile

1501/501

1531/511

gln arg leu arg gln cys lys tyr val lys lys arg val ile leu lys asp leu lys his

1561/521

1591/531

asn asp gly asn phe thr glu lys gln lys ile glu leu asn lys leu leu gln ile asp

1621/541

1651/551

tyr tyr thr leu thr lys phe tyr gly thr val lys leu asp thr met ile phe gly val

1681/561

1711/571

ile glu tyr cys glu arg gly ser leu arg glu val leu asn asp thr ile ser tyr pro

1741/581

1771/591

asp gly thr phe met asp trp glu phe lys ile ser val leu tyr asp ile ala lys gly

1801/601

1831/611

met ser tyr leu his ser ser lys thr glu val his gly arg leu lys ser thr asn cys

1861/621

1891/631

val val asp ser arg met val val lys ile thr asp phe gly cys asn ser ile leu pro

1921/641

1951/651

pro lys lys asp leu trp thr ala pro glu his leu arg gln ala asn ile ser gln lys

1981/661

2011/671

gly asp val tyr ser tyr gly ile ile ala gln glu ile ile leu arg lys glu thr phe

2041/681

2071/691

tyr thr leu ser cys arg asp arg asn glu lys ile phe arg val glu asn ser asp gly

2101/701

2131/711

met lys pro phe arg pro asp leu phe leu glu thr ala glu glu lys glu leu glu val

2161/721

2191/731

tyr leu leu val lys asn cys trp glu glu asp pro glu lys arg pro asp phe lys lys

2221/741

2251/751

ile glu thr thr leu ala lys ile phe gly leu phe his asp gln lys asn glu ser tyr

- 52 -

2281/761 2311/771
met asp thr leu ile arg arg leu gln leu tyr ser arg asn leu glu his leu val glu
2341/781 2371/791
glu arg thr gln leu tyr lys ala glu arg asp arg ala asp arg leu asn phe met leu
2401/801 2431/811
leu pro arg leu val val lys ser leu lys glu lys gly phe val glu pro glu leu tyr
2461/821 2491/831
glu glu val thr ile tyr phe ser asp ile val gly phe thr thr ile cys lys tyr ser
2521/841 2551/851
thr pro met glu val val asp met leu asn asp ile tyr lys ser phe asp his ile val
2581/861 2611/871
asp his his asp val tyr lys val glu thr ile gly asp ala tyr met val ala ser gly
2641/881 2671/891
leu pro lys arg asn gly asn arg his ala ile asp ile ala lys met ala leu glu ile
2701/901 2731/911
leu ser phe met gly thr phe glu leu glu his leu pro gly leu pro ile trp ile arg
2761/921 2791/931
ile gly val his ser gly pro cys ala ala gly val val gly ile lys met pro arg tyr
2821/941 2851/951
cys leu phe gly asp thr val asn thr ala ser arg met glu ser thr gly leu pro leu
2881/961 2911/971
arg ile his val ser gly ser thr ile ala ile leu lys arg thr glu cys gln phe leu
2941/981 2971/991
tyr glu val arg gly glu thr tyr leu lys gly arg gly asn glu thr thr tyr trp leu
3001/1001 3031/1011
thr gly met lys asp gln lys phe asn leu pro thr pro pro thr val glu asn qln qln
3061/1021 3091/1031
arg leu qln ala glu phe ser asp met ile ala asn ser leu qln lys arg qln ala ala
3121/1041 3151/1051
gly ile arg ser qln lys pro arq arg val ala ser tyr lys qly thr leu glu tyr
3181/1061 3211/1071
leu qln leu asn thr thr asp lys glu ser thr tyr phe

SEQ ID NO:3	AGC AAG TGG GCA CAA GGA GTA T
SEQ ID NO:4	GCG TTC ACA GTC ACA TTT AGG C
SEQ ID NO:5	AAG TGG GCA CAA GGA GTA TGG T
SEQ ID NO:6	GCG TTC ACA GTC ACA TTT AGG C
SEQ ID NO:7	AGT GGG CAC AAG GAG TAT GGT T
SEQ ID NO:8	GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:9	AGT GGG CAC AAG GAG TAT GGT T
SEQ ID NO:10	GCG TTC ACA GTC ACA TTT AGG T
SEQ ID NO:11	TGG GCA CAA GGA GTA TGG TTC TA

SEQ ID NO:12 GCG TTC ACA GTC ACA TTT AGG C
SEQ ID NO:13 GGG CAC AAG GAG TAT GGT TCT A
SEQ ID NO:14 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:15 GGG CAC AAG GAG TAT GGT TCT A
SEQ ID NO:16 GTA GCG TTC ACA GTC ACA TTT AGG
SEQ ID NO:17 GGC ACA AGG AGT ATG GTT CTA A
SEQ ID NO:18 GAA AGT AGC GTT CAC AGT CAC A
SEQ ID NO:19 GTG AAT GAG GGG CTG GAA ATA GT
SEQ ID NO:20 GGC AGT CGC CTG AGT TAT GAA T
SEQ ID NO:21 TGA ATG AGG GGC TGG AAA TAG T
SEQ ID NO:22 GGC AGT CGC CTG AGT TAT GAA T
SEQ ID NO:23 TGA ATG AGG GGC TGG AAA TAG T
SEQ ID NO:24 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:25 GAA TGA GGG GCT GGA AAT AGT G
SEQ ID NO:26 CGA GTT CGT GGG AGA AAT AGG A
SEQ ID NO:27 GAA TGA GGG GCT GGA AAT AGT G
SEQ ID NO:28 GGC AGT CGC CTG AGT TAT GAA T
SEQ ID NO:29 GAA TGA GGG GCT GGA AAT AGT G
SEQ ID NO:30 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:31 AAT GAG GGG CTG GAA ATA GTG A
SEQ ID NO:32 CGA GTT CGT GGG AGA AAT AGG A
SEQ ID NO:33 AAT GAG GGG CTG GAA ATA GTG A
SEQ ID NO:34 GGC AGT CGC CTG AGT TAT GAA T
SEQ ID NO:35 ATG AGG GGC TGG AAA TAG TGA G
SEQ ID NO:36 CGA GTT CGT GGG AGA AAT AGG A
SEQ ID NO:37 ATG AGG GGC TGG AAA TAG TGA G
SEQ ID NO:38 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:39 GAG GGG CTG GAA ATA GTG AGA G
SEQ ID NO:40 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:41 GGG CTG GAA ATA GTG AGA GGA CG
SEQ ID NO:42 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:43 GGG CTG GAA ATA GTG AGA GGA C
SEQ ID NO:44 CAG TCG CCT GAG TTA TGA ATC A
SEQ ID NO:45 GGG CTG GAA ATA GTG AGA GGA CG

- 54 -

SEQ ID NO:46 CGA GTT CGT GGG AGA AAT AGG A
SEQ ID NO:47 GGG CTG GAA ATA GTG AGA GGA CG
SEQ ID NO:48 GGC AGT CGC CTG AGT TAT GAA T
SEQ ID NO:49 CGG ATG GTC TGA TTC ATA ACT C
SEQ ID NO:50 GTG GGA GAA ATA GGA AAC GCT A
SEQ ID NO:51 CTG GAG CAC TTC GTA TGT TTA C
SEQ ID NO:52 GGT GAT AGA TTC CTG GAG AAA G
SEQ ID NO:53 GTT TCC TAT TTC TCC CAC GAA CTC
SEQ ID NO:54 TTT CTT GGT GTC CAC AGA GGT A
SEQ ID NO:55 GTT TCC TAT TTC TCC CAC GAA C
SEQ ID NO:56 CGT CAT ACC CTT CAA AAG TGA G
SEQ ID NO:57 GTT TCC TAT TTC TCC CAC GAA CTC
SEQ ID NO:58 GAA CTC TGG ACC ACC ACA CAT AA
SEQ ID NO:59 GGA CCA CAA CAG GAA AAG CAA TG
SEQ ID NO:60 AGG CAA GAG CAA AGT CTC GTT T
SEQ ID NO:61 GGA CCA CAA CAG GAA AAG CAA T
SEQ ID NO:62 CAG CGT CAG AAC AAG GAC ATT T
SEQ ID NO:63 GAC TAT AAA GAA ACC TTA ACC AGG C
SEQ ID NO:64 GGA CCA CCA CAC ATA ATA ATC AC
SEQ ID NO:65 CCT TGA CAC AGA ATT GAG CTA C
SEQ ID NO:66 GGA CCA CCA CAC ATA ATA ATC AC
SEQ ID NO:67 AAT GAG GGG CTG GAA ATA GTG AG
SEQ ID NO:68 GCA GTC GCC TGA GTT ATG AAT C
SEQ ID NO:69 GTC CTG GAT CCC CCA GGT GAG TCA GAA CTG CC
SEQ ID NO:70 GGC CGA ATT CGG TGC TAC TCC GGC AGT CGC C
SEQ ID NO:71 TCA TGG ATC CGG CGA CTG CCG GAG TAG CAC C
SEQ ID NO:72 GGA ATT CCC AGG AGA CAG CG
SEQ ID NO:73 : ATT-GCA-GTC-TTC-ACC-CTC-ACT-GGA-GCT-GTG-GTG-CTG-CTC-CTG-CTC-GTC-
 GCT-CTC-CTG-ATG-CTC
SEQ ID NO:74 : TAA-CGT-CAG-AAG-TGG-GAG-TGA-CCT-CGA-CAC-CAC-GAC-GAG-GAC-GAG-CAG-
 CGA-GAG-GAC-TAC-GAG

CLAIMS

1. An *in vitro* method of determining whether or not an individual has metastasized colorectal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluids from an individual to determine whether ST receptor protein is being expressed by cells in said sample; wherein expression of ST receptor protein is determined by either
 - a) detecting the presence of protein in said sample that binds to antibodies that specifically bind to amino acids 24-430 or 1031-1093 of human ST receptor protein or
 - b) detecting the presence of mRNA in said sample that encodes amino acids 24-430 or 1031-1093 of human ST receptor protein.
- 15 2. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 24-430 or 1031-1093 of human ST receptor protein.
- 20 3. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 24-430 of human ST receptor protein.
- 25 4. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 1031-1093 of human ST receptor protein.
- 30 5. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST

- 56 -

receptor protein, said primers hybridize to sequences that encode amino acids 24-430 or 1031-1093 of human ST receptor protein.

6. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST receptor protein, said primers hybridize to sequences that encode amino acids 24-430 of human ST receptor protein.

10 7. The method of claim 1 wherein expression of said ST receptor protein by said cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST receptor protein, said primers hybridize to sequences that 15 encode amino acids 1031-1093 of human ST receptor protein.

8. An in vitro method of determining whether or not a tumor cell is a colorectal tumor cell comprising the steps of determining whether said tumor cell expresses ST receptor protein; wherein expression of ST receptor protein is 20 determined by either

a) detecting the presence of protein in said sample that binds to antibodies that specifically bind to human ST receptor protein at an epitope that comprises amino acids 24-430 or 1031-1093 of or

25 b) detecting the presence of mRNA in said sample that encodes amino acids 24-430 or 1031-1093 of human ST receptor protein.

9. The method of claim 8 wherein expression of said ST receptor protein by said tumor cells is determined by 30 immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 24-430 or 1031-1093 of human ST receptor protein.

10. The method of claim 8 wherein expression of said ST receptor protein by said cells is determined by immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 24-430 of human ST receptor protein.

11. The method of claim 8 wherein expression of said ST receptor protein by said cells is determined by immunoassay wherein said tissue sample is contacted with detectable antibodies that specifically bind to an epitope within amino acids 1031-1093 of human ST receptor protein.

12. The method of claim 8 wherein expression of said ST receptor protein by said tumor cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST receptor protein, said primers hybridize to sequences that encode amino acids 24-430 or 1031-1093 of human ST receptor protein.

13. The method of claim 8 wherein expression of said ST receptor protein by said cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST receptor protein, said primers hybridize to sequences that encode amino acids 24-430 of human ST receptor protein.

14. The method of claim 13 wherein at least one primer is selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID

NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,
SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID
NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53,
SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID
5 NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62,
SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID
NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70,, SEQ ID NO:71
and SEQ ID NO:72.

15. The method of claim 13 wherein said primers are a pair
10 of primers selected from the group consisting of: SEQ ID NO:3
and SEQ ID NO:4; SEQ ID NO:5 and SEQ ID NO:6; SEQ ID NO:7 and
SEQ ID NO:8; SEQ ID NO:9 and SEQ ID NO:10; SEQ ID NO:11 and SEQ
ID NO:12; SEQ ID NO:13 and SEQ ID NO:14; SEQ ID NO:15 and SEQ
ID NO:16; SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:19 and SEQ
15 ID NO:20; SEQ ID NO:21 and SEQ ID NO:22; SEQ ID NO:23 and SEQ
ID NO:24; SEQ ID NO:25 and SEQ ID NO:26; SEQ ID NO:27 and SEQ
ID NO:28; SEQ ID NO:29 and SEQ ID NO:30; SEQ ID NO:31 and SEQ
ID NO:32; SEQ ID NO:33 and SEQ ID NO:34; SEQ ID NO:35 and SEQ
ID NO:36; SEQ ID NO:37 and SEQ ID NO:38; SEQ ID NO:39 and SEQ
20 ID NO:40; SEQ ID NO:41 and SEQ ID NO:42; SEQ ID NO:43 and SEQ
ID NO:44; SEQ ID NO:45 and SEQ ID NO:46; SEQ ID NO:47 and SEQ
ID NO:48; SEQ ID NO:49 and SEQ ID NO:50; SEQ ID NO:51 and SEQ
ID NO:52; SEQ ID NO:53 and SEQ ID NO:54; SEQ ID NO:55 and SEQ
ID NO:56; SEQ ID NO:57 and SEQ ID NO:58; SEQ ID NO:59 and SEQ
25 ID NO:60; SEQ ID NO:61 and SEQ ID NO:62; SEQ ID NO:63 and SEQ
ID NO:64; SEQ ID NO:65 and SEQ ID NO:66; SEQ ID NO:67 and SEQ
ID NO:68; SEQ ID NO:69 and SEQ ID NO:70; and SEQ ID NO:71 and
SEQ ID NO:72.

16. The method of claim 8 wherein expression of said ST
30 receptor protein by said cells is determined by polymerase chain reaction wherein said tissue sample is contacted with primers that selectively amplify mRNA or cDNA that encodes ST receptor protein, said primers hybridize to sequences that encode amino acids 1031-1093 of human ST receptor protein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/07467

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :G01N 33/574, 33/53; C12Q 1/68

US CL :435/6, 7.23, 7.9; 436/63, 64, 501, 813

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.23, 7.9; 436/63, 64, 501, 813

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,601,990 A (S.A. WALDMAN) 11 February 1997, columns 4, 5 and 6.	1-16
Y, P	US 5,518,888 A (S.A. WALDMAN) 21 May 1996, columns 4-10 and the amino acid sequences set forth in columns 49-70.	1-16
Y	US 4,584,268 A (R.L. CERIANI et al.) 22 April 1986, columns 1 and 2.	1-16
Y	US 5,237,051 A (D.L. GARBERS et al.) 17 August 1993, column 1, lines 30-55.	1-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
* "O" document referring to an oral disclosure, use, exhibition or other means		
* "P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
14 JUNE 1997	07 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>E. Miller Jr.</i> TONI R. SCHEINER
Faximile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/07467

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS; DIALOG: file biochem

Search terms: ST receptor, enterotoxin receptor, heat-stable toxin, colorectal, colon, intestin?, jejunum, ilium, cancer, carcinoma, metasta?, neoplas?, antibod?, hybridiz?

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.